<div class="hlFld-Fulltext">
<div xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:urlutil="java:com.atypon.literatum.customization.UrlUtil" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="boxed-text-float" id="d3e542">
<div id="acd3e544" class="anchor-spacer"></div>
<h2 class="article-section__title section__title" id="d3e544">Clinical Perspective</h2>
<div id="acd3e549" class="anchor-spacer"></div>
<h3 class="article-section__title to-section " id="d3e549">What Is New?</h3>
<ul class="NLM_list-list_type-bullet">
<li><p class="inline">Canagliflozin
 is currently not approved for the treatment of type 2 diabetes in 
people with estimated glomerular filtration rate (eGFR) &lt;45 
mL/min/1.73 m<sup>2</sup> because glycemic efficacy is dependent on kidney function.</p></li>
<li><p class="inline">In
 the CANVAS Program, the effect of canagliflozin on glycohemoglobin was 
progressively attenuated at lower eGFR levels, but blood pressure and 
body weight reductions were comparable.</p></li>
<li><p class="inline">The
 reduction in risk of major adverse cardiovascular events, 
hospitalization for heart failure, and progression of kidney disease 
appeared similar across different levels of kidney function down to eGFR
 30 mL/min/1.73 m<sup>2</sup>.</p></li>
<li><p class="inline">Safety outcomes were also mostly consistent, but risk of hypoglycemia may increase as eGFR declines.</p></li>
</ul>
<div id="acd3e580" class="anchor-spacer"></div>
<h3 class="article-section__title to-section " id="d3e580">What Are the Clinical Implications?</h3>
<ul class="NLM_list-list_type-bullet">
<li><p class="inline">People
 with type 2 diabetes and chronic kidney disease are at high risk of 
cardiovascular events and progression to end-stage kidney disease.</p></li>
<li><p class="inline">Canagliflozin
 could be considered for the management of type 2 diabetes in people at 
high cardiovascular risk with eGFR down to 30 mL/min/1.73 m<sup>2</sup> to reduce the risk of both cardiovascular and renal outcomes.</p></li>
<li><p class="inline">Reconsidering
 current eGFR-based limitations on the use of canagliflozin may allow 
additional individuals to benefit from this therapy.</p></li>
</ul>
</div>
<div id="acd3e605" class="anchor-spacer"></div>
<h3 class="article-section__title to-section " id="d3e605">Introduction</h3>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Excess mortality and morbidity in type 2 diabetes primarily result from cardiovascular and kidney disease.<sup><a data-tab="pane-pcw-references" href="#R1" id="R1R" class="tab-link">1</a>,<a data-tab="pane-pcw-references" href="#R2" id="R2R" class="tab-link">2</a></sup>
 Sodium glucose cotransporter 2 (SGLT2) inhibitors are a class of 
medications that promote urinary glucose excretion and natriuresis, and 
alter glomerular hemodynamics.<sup><a data-tab="pane-pcw-references" href="#R3" id="R3R" class="tab-link">3</a></sup>
 These changes have been noted to result in improvements in glycemic 
status, blood pressure, weight, and proteinuria in patients with type 2 
diabetes,<sup><a data-tab="pane-pcw-references" href="#R3" id="R3R" class="tab-link">3</a></sup>
 and have translated into a reduction in cardiovascular events and 
preservation of kidney function in large cardiovascular outcome trials.<sup><a data-tab="pane-pcw-references" href="#R4%20R5%20R6" id="R4 R5 R6R" class="tab-link">4–6</a></sup></p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 glucose-lowering effect of SGLT2 inhibitors is reliant on glomerular 
filtration. Previous studies have shown that the glycemic efficacy of 
SGLT2 inhibitors is attenuated in people with chronic kidney disease 
(CKD), defined as an estimated glomerular filtration rate (eGFR) &lt;60 
mL/min/1.73 m<sup>2</sup>.<sup><a data-tab="pane-pcw-references" href="#R7" id="R7R" class="tab-link">7</a>,<a data-tab="pane-pcw-references" href="#R8" id="R8R" class="tab-link">8</a></sup>
 As such, these agents are not currently recommended for use in people 
with significantly reduced kidney function, defined as an eGFR &lt;45 
mL/min/1.73 m<sup>2</sup> with canagliflozin and empagliflozin or &lt;60 mL/min/1.73 m<sup>2</sup> with dapagliflozin and ertugliflozin.<sup><a data-tab="pane-pcw-references" href="#R9" id="R9R" class="tab-link">9</a>,<a data-tab="pane-pcw-references" href="#R10" id="R10R" class="tab-link">10</a></sup>
 Conversely, the efficacy of SGLT2 inhibitors at reducing blood pressure
 and proteinuria may be maintained in people with diabetes and CKD.<sup><a data-tab="pane-pcw-references" href="#R8" id="R8R" class="tab-link">8</a>,<a data-tab="pane-pcw-references" href="#R11" id="R11R" class="tab-link">11</a></sup></p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">As
 individuals with CKD are among the highest-risk groups for 
cardiovascular disease and progression to end-stage kidney disease,<sup><a data-tab="pane-pcw-references" href="#R12" id="R12R" class="tab-link">12</a></sup>
 it is important to understand whether the benefits of SGLT2 inhibitors 
for cardiovascular events and progression of renal disease are similar 
to those in people with normal kidney function.</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">We
 undertook a range of post hoc analyses of data from the CANVAS Program 
to determine the effect of canagliflozin on cardiovascular, renal, and 
safety outcomes across different levels of kidney function to better 
understand whether this agent may have a role in people with type 2 
diabetes and CKD at high cardiovascular risk, including those with eGFR 
between 30 and 45 mL/min/1.73 m<sup>2</sup> for whom this treatment is not currently approved.</p>
<div id="acd3e678" class="anchor-spacer"></div>
<h3 class="article-section__title to-section " id="d3e678">Methods</h3>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Data from the CANVAS Program will be made available in the public domain via the Yale University Open Data Access Project (<a class="references__uri" href="http://yoda.yale.edu/">http://yoda.yale.edu/</a>)
 once the product and relevant indication studied have been approved by 
regulators in the United States and European Union, and the study has 
been completed for 18 months. The trial protocols and statistical 
analysis plans were published along with the primary CANVAS Program 
manuscript.<sup><a data-tab="pane-pcw-references" href="#R4" id="R4R" class="tab-link">4</a></sup></p>
<div id="acd3e692" class="anchor-spacer"></div>
<h4 class="article-section__title" id="d3e692">Study Design and Participants</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 CANVAS Program comprised 2 multicenter, double-blind, 
placebo-controlled, randomized trials, CANVAS and CANVAS-R, conducted in
 comparable populations and designed to collectively assess the 
cardiovascular safety and efficacy of canagliflozin, as well as its 
effect on renal and adverse outcomes, in subjects with type 2 diabetes 
and a history or high risk of cardiovascular disease. Both trials were 
scheduled for joint closeout and analysis when at least 688 
cardiovascular events occurred and the last randomized participant had 
undergone at least 78 weeks of follow-up.<sup><a data-tab="pane-pcw-references" href="#R4" id="R4R" class="tab-link">4</a></sup>
 Local institutional ethics committees approved the trial protocols at 
each site, and these are available online (ClinicalTrials.gov 
NCT01032629 and NCT01989754). All participants provided written informed
 consent.</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 main entry criteria for both trials were identical and included 
participants with type 2 diabetes (glycohemoglobin [HbA1c] ≥7.0% and 
≤10.5%) who were either ≥30 years old with established atherosclerotic 
vascular disease or ≥50 years old with 2 or more cardiovascular risk 
factors. These risk factors included duration of diabetes of at least 10
 years; systolic blood pressure &gt;140 mm Hg while receiving 1 or more 
antihypertensive agents; current smoking; microalbuminuria or 
macroalbuminuria; or high-density lipoprotein cholesterol level &lt;1 
mmol/L. Participants with a baseline eGFR &lt;30 mL/min/1.73 m<sup>2</sup> were excluded.</p>
<div id="acd3e711" class="anchor-spacer"></div>
<h4 class="article-section__title" id="d3e711">Randomization and Masking</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">All
 potentially eligible participants underwent a 2-week, single-blind, 
placebo run-in period before randomization. Participants in CANVAS were 
randomly assigned in a 1:1:1 ratio to receive canagliflozin 100 mg 
daily, canagliflozin 300 mg daily, or placebo, while participants in 
CANVAS-R were randomly assigned in a 1:1 ratio to receive canagliflozin 
100 mg daily or matching placebo, with an optional increase to 300 mg or
 matching placebo daily starting from week 13. Randomization was 
performed centrally through a web-based response system with the use of a
 computer-generated randomization schedule with randomly permuted blocks
 that were prepared by the trial sponsor. All participants and trial 
staff were blinded to individual treatment allocations until the end of 
the trial.</p>
<div id="acd3e720" class="anchor-spacer"></div>
<h4 class="article-section__title" id="d3e720">Procedures</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Face-to-face
 follow-up was scheduled at least 3 times in the first year and at 
intervals of every 6 months thereafter with telephone follow-up between 
face-to-face assessments. Serum creatinine was measured at least 3 times
 in the first year, and then once every 26 weeks. Urine 
albumin/creatinine ratio (UACR) was measured at week 12, and then 
annually in CANVAS, and every 26 weeks in CANVAS-R. Off-treatment serum 
creatinine was measured approximately 30 days after cessation of 
randomized treatment in CANVAS-R participants. Adverse event assessment 
was performed at each visit. Other glycemic and cardiovascular risk 
factor management, including renin-angiotensin system (RAS) blockade, 
was guided by best practice in accordance with local guidelines.</p>
<div id="acd3e730" class="anchor-spacer"></div>
<h4 class="article-section__title" id="d3e730">Outcomes</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Definitions for the clinical outcomes of the CANVAS Program have been previously published.<sup><a data-tab="pane-pcw-references" href="#R4" id="R4R" class="tab-link">4</a></sup></p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 primary outcome was a composite of death from cardiovascular causes, 
nonfatal myocardial infarction, or nonfatal stroke. Other secondary 
cardiovascular outcomes included cardiovascular death, fatal/nonfatal 
myocardial infarction, fatal/nonfatal stroke, and hospitalization for 
heart failure.</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 main renal outcomes were sustained and independently adjudicated 
composites of end-stage kidney disease, renal death, and either 40% 
decrease in eGFR or doubling of serum creatinine. End points of 40% 
reduction in eGFR and doubling of serum creatinine were sent for 
adjudication if sustained for 2 consecutive measures of ≥30 days apart 
or occurring on the last available measure. Further analyses of the 
adjusted mean eGFR slope difference between canagliflozin and placebo 
groups were also performed. Central end point adjudication committees 
blinded to treatment allocation assessed cardiovascular, renal, and key 
safety outcomes.</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 Modification of Diet in Renal Disease Study equation was used to 
calculate eGFR based on centrally measured serum creatinine collected at
 study visits. Albuminuria was measured in first-morning void urine 
specimens and calculated as a UACR.</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Adverse
 events, both serious and nonserious, were collected and reported for 
the CANVAS trial until January 2014, as mandated by the US Food and Drug
 Administration and other regulatory bodies as a requirement for initial
 approval for the use of canagliflozin. After this time, only serious 
adverse events, adverse events leading to study drug discontinuation, or
 selected adverse events of interest were collected in the CANVAS trial.
 We therefore reported all adverse events for the CANVAS trial 
separately, along with all serious adverse events across the CANVAS 
Program (CANVAS and CANVAS-R).</p>
<div id="acd3e755" class="anchor-spacer"></div>
<h4 class="article-section__title" id="d3e755">Statistical Analysis</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Baseline characteristics across eGFR subgroups were compared using χ<sup>2</sup> and ANOVA tests for dichotomous and categorical variables.</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 effects of canagliflozin on the primary and other cardiovascular, 
renal, and safety outcomes were analyzed in participants with and 
without CKD (defined as &lt;60 and ≥60 mL/min/1.73 m<sup>2</sup>. 
Analyses were also conducted for all outcomes using more granular eGFR 
categories (&lt;45, 45 to &lt;60, 60 to &lt;90, and ≥90 mL/min/1.73 m<sup>2</sup>.</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Hazard
 ratios (HRs) and 95% CIs for primary and other cardiovascular and renal
 outcomes were estimated with Cox regression models, with stratification
 according to trial and history of cardiovascular disease (except for 
renal outcomes) using an intention-to-treat approach, for all 
canagliflozin groups combined versus placebo. Annualized incidence rates
 were calculated per 1000 patient-years of follow-up. Sensitivity 
analyses adjusting for competing risk of death were performed for the 
main cardiovascular and renal outcomes using the Fine and Gray method.<sup><a data-tab="pane-pcw-references" href="#R13" id="R13R" class="tab-link">13</a></sup></p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 average change in eGFR over time and the differences between 
canagliflozin and placebo arms were assessed by a piecewise linear 
mixed-effect model in 2 time periods: baseline to week 13, and week 13 
to last available measures during the trial period, using an 
intention-to-treat approach. A time spline variable measuring the 
follow-up time from week 13 was introduced in the model to accommodate 
the nonlinear trends of the eGFR time trajectory. eGFR data collected at
 the scheduled visits were regressed by the fixed effects with terms for
 treatment and study, and with linear covariates of time, time spline, 
and interactions of treatment by time and treatment by the spline 
variable. Intercept, time, and time spline were included as random 
effects to allow variation between participants. Time covariates 
included in the model were calculated in years in order to estimate 
annualized changes in eGFR. In CANVAS-R, the difference in change from 
baseline to off-treatment eGFR levels between the canagliflozin and 
placebo arms was assessed based on serum creatinine measurements 
approximately 30 days after treatment discontinuation.</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 effect of canagliflozin on intermediate markers of cardiovascular risk,
 including HbA1c, blood pressure, and body weight, were calculated as 
mean change from baseline across the entire follow-up period. The 
average change in these continuous outcomes (HbA1c, blood pressure, and 
body weight) over time, and the difference between canagliflozin and 
placebo, were analyzed using mixed-effect models for repeated 
measurements that included all the post-baseline data up to week 338 and
 the covariates for study, visit, treatment, baseline measures, 
treatment-by-visit, and baseline-by-visit interactions. Due to the 
highly skewed distribution of UACR data, UACR were log-transformed, and 
the geometric mean of post-baseline UACR was estimated using the similar
 mixed-effect model. Changes in albuminuria were calculated as the ratio
 of the geometric mean of postrandomization UACR measures with 
canagliflozin compared to placebo.</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Heterogeneity
 of treatment effect across different levels of kidney function was 
tested by adding eGFR as a covariate and a term for eGFR by treatment 
interaction to the relevant model. Terms for eGFR by time interaction 
were also included in the piecewise linear mixed model. The global <i>P</i>
 values for heterogeneity across all levels of baseline eGFR were 
obtained through the likelihood ratio test. For major cardiovascular, 
renal, and safety outcomes, further analyses were performed, 
investigating effect modification by eGFR as a continuous variable.</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">For
 safety outcomes, on-treatment analysis was performed (with data from 
participants who had a safety outcome while they were receiving 
canagliflozin or placebo, or within 30 days after discontinuation of the
 drug or placebo). The exception was for amputation and fracture 
outcomes, where analyses included participants who received at least 1 
dose of canagliflozin or placebo and had an event at any time during 
follow-up.</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Absolute
 risk differences for the primary outcome, hospitalization for heart 
failure, progression to the composite renal outcome, and risk of 
amputation were estimated by subtracting the incidence rates (per 1000 
patient-years) of placebo from those of canagliflozin and multiplying by
 5 years. The CIs for these estimates were similarly calculated by 
multiplying both the lower and upper CI values (which were estimated 
using the method described by Altman and Andersen<sup><a data-tab="pane-pcw-references" href="#R14" id="R14R" class="tab-link">14</a></sup>)
 by 5. The heterogeneity tests for absolute risk differences were 
performed using a nonlinear mixed-effect model with treatment, subgroup,
 and treatment-by-subgroup interaction as the covariates.</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Analyses were performed with SAS software, version 9.2, and SAS Enterprise Guide, version 7.11.</p>
<div id="acd3e808" class="anchor-spacer"></div>
<h4 class="article-section__title" id="d3e808">Role of the Funding Source</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 trials were sponsored by Janssen Research &amp; Development, LLC, and 
were conducted collaboratively by the sponsor, an academic steering 
committee, and an academic research organization, George Clinical. The 
sponsor was responsible for study oversight and data collection, and had
 a representative on the Steering Committee, which was responsible for 
study design, data analysis, data interpretation, and writing of this 
report. All authors had full access to all the data and had final 
responsibility for the decision to submit for publication.</p>
<div id="acd3e818" class="anchor-spacer"></div>
<h3 class="article-section__title to-section " id="d3e818">Results</h3>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 CANVAS Program randomized 10 142 participants with a mean follow-up 
duration of 188.2 weeks. At baseline, 2039 (20.1%) participants had CKD 
(mean age, 68 years; blood pressure, 137/76 mm Hg; HbA1c, 8.3%; eGFR, 49
 mL/min/1.73 m<sup>2</sup>; median UACR, 22 mg/g), of whom 71.6% had a 
prior history of cardiovascular disease. This included 554 participants 
(5.5%) in the eGFR &lt;45 mL/min/1.73 m<sup>2</sup> category, among whom 73.3% had a history of cardiovascular disease.</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Baseline characteristics of participants with eGFR &lt;45, 45 to &lt;60, 60 to &lt;90, and ≥90 mL/min/1.73 m<sup>2</sup> are presented in <a class="ref showTableEvent" data-id="T1" href="#T1">Table 1</a>.
 In progressively lower categories of eGFR, participants were older and 
more likely to be female; be white; have a longer duration of diabetes; 
have established micro- or macrovascular disease; have a history of 
heart failure, micro- or macroalbuminuria; and be treated with insulin 
and cardiovascular protective therapies (all <i>P</i>&lt;0.0001). 
Baseline characteristics for participants with and without CKD were well
 balanced across randomized groups and have been previously published.<sup><a data-tab="pane-pcw-references" href="#R15" id="R15R" class="tab-link">15</a></sup></p>
<div id="T1" class="anchor-spacer"></div>
<div class="article-table-content" id="T1">
<table class="table article-section__table">
<caption><strong><p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns"><strong class="captionLabel">Table 1.</strong> Characteristics of Participants With eGFR &lt;45, 45 to &lt;60, 60 to &lt;90, and ≥90 mL/min/1.73 m<sup>2</sup> at Baseline<a class="ref showTableEvent" data-id="tab1fn2" href="#tab1fn2">*</a></p></strong></caption>
<thead xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns"><tr>
<th colspan="1" rowspan="1" align="left"></th>
<th colspan="1" rowspan="1" align="center">eGFR &lt;45 mL/min/1.73 m<sup>2</sup> (N = 554)</th>
<th colspan="1" rowspan="1" align="center">eGFR 45 to &lt;60 mL/min/1.73 m<sup>2</sup> (N = 1485)</th>
<th colspan="1" rowspan="1" align="center">eGFR 60 to &lt;90 mL/min/1.73 m<sup>2</sup> (N = 5625)</th>
<th colspan="1" rowspan="1" align="center">eGFR ≥90 mL/min/1.73 m<sup>2</sup> (N = 2476)</th>
</tr></thead>
<tbody xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">
<tr>
<td colspan="1" rowspan="1" align="left">Age, y, mean (SD)</td>
<td colspan="1" rowspan="1" align="center">68.7 (8.0)</td>
<td colspan="1" rowspan="1" align="center">67.2 (7.6)</td>
<td colspan="1" rowspan="1" align="center">63.6 (7.6)</td>
<td colspan="1" rowspan="1" align="center">59.0 (7.9)</td>
</tr>
<tr><td colspan="5" rowspan="1" align="left">Sex, No. (%)</td></tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Male</td>
<td colspan="1" rowspan="1" align="center">309 (55.8)</td>
<td colspan="1" rowspan="1" align="center">877 (59.1)</td>
<td colspan="1" rowspan="1" align="center">3674 (65.3)</td>
<td colspan="1" rowspan="1" align="center">1648 (66.6)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Female</td>
<td colspan="1" rowspan="1" align="center">245 (44.2)</td>
<td colspan="1" rowspan="1" align="center">608 (40.9)</td>
<td colspan="1" rowspan="1" align="center">1951 (34.7)</td>
<td colspan="1" rowspan="1" align="center">828 (33.4)</td>
</tr>
<tr><td colspan="5" rowspan="1" align="left">Race, No. (%)</td></tr>
<tr>
<td colspan="1" rowspan="1" align="left"> White</td>
<td colspan="1" rowspan="1" align="center">461 (83.2)</td>
<td colspan="1" rowspan="1" align="center">1212 (81.6)</td>
<td colspan="1" rowspan="1" align="center">4475 (79.6)</td>
<td colspan="1" rowspan="1" align="center">1794 (72.5)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Asian</td>
<td colspan="1" rowspan="1" align="center">53 (9.6)</td>
<td colspan="1" rowspan="1" align="center">163 (11.0)</td>
<td colspan="1" rowspan="1" align="center">716 (12.7)</td>
<td colspan="1" rowspan="1" align="center">352 (14.2)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Black or African American</td>
<td colspan="1" rowspan="1" align="center">16 (2.9)</td>
<td colspan="1" rowspan="1" align="center">30 (2.0)</td>
<td colspan="1" rowspan="1" align="center">137 (2.4)</td>
<td colspan="1" rowspan="1" align="center">153 (6.2)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Other<a class="ref showTableEvent" data-id="tab1fn3" href="#tab1fn3">†</a>
</td>
<td colspan="1" rowspan="1" align="center">23 (4.3)</td>
<td colspan="1" rowspan="1" align="center">80 (5.4)</td>
<td colspan="1" rowspan="1" align="center">297 (5.3)</td>
<td colspan="1" rowspan="1" align="center">177 (7.2)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Current smoker, No. (%)</td>
<td colspan="1" rowspan="1" align="center">64 (11.6)</td>
<td colspan="1" rowspan="1" align="center">162 (10.9)</td>
<td colspan="1" rowspan="1" align="center">949 (16.9)</td>
<td colspan="1" rowspan="1" align="center">631 (25.5)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">History of hypertension, No. (%)</td>
<td colspan="1" rowspan="1" align="center">524 (94.6)</td>
<td colspan="1" rowspan="1" align="center">1404 (94.6)</td>
<td colspan="1" rowspan="1" align="center">5083 (90.4)</td>
<td colspan="1" rowspan="1" align="center">2112 (85.3)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">History of heart failure, No. (%)</td>
<td colspan="1" rowspan="1" align="center">115 (20.8)</td>
<td colspan="1" rowspan="1" align="center">249 (16.8)</td>
<td colspan="1" rowspan="1" align="center">805 (14.3)</td>
<td colspan="1" rowspan="1" align="center">291 (11.8)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Duration of diabetes, y, mean (SD)</td>
<td colspan="1" rowspan="1" align="center">16.8 (8.3)</td>
<td colspan="1" rowspan="1" align="center">15.6 (8.3)</td>
<td colspan="1" rowspan="1" align="center">13.4 (7.6)</td>
<td colspan="1" rowspan="1" align="center">11.9 (7.0)</td>
</tr>
<tr><td colspan="5" rowspan="1" align="left">Drug therapy, No. (%)</td></tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Insulin</td>
<td colspan="1" rowspan="1" align="center">367 (66.3)</td>
<td colspan="1" rowspan="1" align="center">877 (59.0)</td>
<td colspan="1" rowspan="1" align="center">2766 (49.2)</td>
<td colspan="1" rowspan="1" align="center">1085 (43.8)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Sulfonylurea</td>
<td colspan="1" rowspan="1" align="center">181 (32.7)</td>
<td colspan="1" rowspan="1" align="center">577 (38.9)</td>
<td colspan="1" rowspan="1" align="center">2460 (43.7)</td>
<td colspan="1" rowspan="1" align="center">1141 (46.1)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Metformin</td>
<td colspan="1" rowspan="1" align="center">222 (40.1)</td>
<td colspan="1" rowspan="1" align="center">940 (63.3)</td>
<td colspan="1" rowspan="1" align="center">4534 (80.6)</td>
<td colspan="1" rowspan="1" align="center">2129 (86.0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> GLP-1 receptor agonist</td>
<td colspan="1" rowspan="1" align="center">22 (4.0)</td>
<td colspan="1" rowspan="1" align="center">61 (4.1)</td>
<td colspan="1" rowspan="1" align="center">217 (3.9)</td>
<td colspan="1" rowspan="1" align="center">107 (4.3)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> DPP-4 inhibitor</td>
<td colspan="1" rowspan="1" align="center">87 (15.7)</td>
<td colspan="1" rowspan="1" align="center">196 (13.2)</td>
<td colspan="1" rowspan="1" align="center">677 (12.0)</td>
<td colspan="1" rowspan="1" align="center">301 (12.2)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Statin</td>
<td colspan="1" rowspan="1" align="center">460 (83.0)</td>
<td colspan="1" rowspan="1" align="center">1130 (76.1)</td>
<td colspan="1" rowspan="1" align="center">4239 (75.4)</td>
<td colspan="1" rowspan="1" align="center">1771 (71.5)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Antithrombotic</td>
<td colspan="1" rowspan="1" align="center">438 (79.1)</td>
<td colspan="1" rowspan="1" align="center">1181 (79.5)</td>
<td colspan="1" rowspan="1" align="center">4142 (73.6)</td>
<td colspan="1" rowspan="1" align="center">1710 (69.0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> RAAS inhibitor</td>
<td colspan="1" rowspan="1" align="center">438 (79.1)</td>
<td colspan="1" rowspan="1" align="center">1217 (82.0)</td>
<td colspan="1" rowspan="1" align="center">4558 (81.0)</td>
<td colspan="1" rowspan="1" align="center">1901 (76.8)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Beta blocker</td>
<td colspan="1" rowspan="1" align="center">363 (65.5)</td>
<td colspan="1" rowspan="1" align="center">912 (61.4)</td>
<td colspan="1" rowspan="1" align="center">3038 (54.0)</td>
<td colspan="1" rowspan="1" align="center">1107 (44.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Diuretic</td>
<td colspan="1" rowspan="1" align="center">361 (65.2)</td>
<td colspan="1" rowspan="1" align="center">861 (58.0)</td>
<td colspan="1" rowspan="1" align="center">2453 (43.6)</td>
<td colspan="1" rowspan="1" align="center">815 (32.9)</td>
</tr>
<tr><td colspan="5" rowspan="1" align="left">Microvascular disease history, No. (%)</td></tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Retinopathy</td>
<td colspan="1" rowspan="1" align="center">157 (28.3)</td>
<td colspan="1" rowspan="1" align="center">398 (26.8)</td>
<td colspan="1" rowspan="1" align="center">1177 (20.9)</td>
<td colspan="1" rowspan="1" align="center">397 (16.0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Nephropathy</td>
<td colspan="1" rowspan="1" align="center">250 (45.1)</td>
<td colspan="1" rowspan="1" align="center">399 (26.9)</td>
<td colspan="1" rowspan="1" align="center">804 (14.3)</td>
<td colspan="1" rowspan="1" align="center">321 (13.0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Neuropathy</td>
<td colspan="1" rowspan="1" align="center">196 (35.4)</td>
<td colspan="1" rowspan="1" align="center">498 (33.5)</td>
<td colspan="1" rowspan="1" align="center">1734 (30.8)</td>
<td colspan="1" rowspan="1" align="center">682 (27.5)</td>
</tr>
<tr><td colspan="5" rowspan="1" align="left">Atherosclerotic vascular disease history, No. (%)<a class="ref showTableEvent" data-id="tab1fn4" href="#tab1fn4">‡</a>
</td></tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Coronary</td>
<td colspan="1" rowspan="1" align="center">348 (62.8)</td>
<td colspan="1" rowspan="1" align="center">924 (62.2)</td>
<td colspan="1" rowspan="1" align="center">3247 (57.7)</td>
<td colspan="1" rowspan="1" align="center">1202 (48.6)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Cerebrovascular</td>
<td colspan="1" rowspan="1" align="center">132 (23.8)</td>
<td colspan="1" rowspan="1" align="center">325 (21.9)</td>
<td colspan="1" rowspan="1" align="center">1059 (18.8)</td>
<td colspan="1" rowspan="1" align="center">441 (17.8)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Peripheral</td>
<td colspan="1" rowspan="1" align="center">146 (26.4)</td>
<td colspan="1" rowspan="1" align="center">359 (24.2)</td>
<td colspan="1" rowspan="1" align="center">1092 (19.4)</td>
<td colspan="1" rowspan="1" align="center">516 (20.8)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Any</td>
<td colspan="1" rowspan="1" align="center">436 (78.7)</td>
<td colspan="1" rowspan="1" align="center">1146 (77.2)</td>
<td colspan="1" rowspan="1" align="center">4050 (72.0)</td>
<td colspan="1" rowspan="1" align="center">1691 (68.3)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">CV disease history, No. (%)<a class="ref showTableEvent" data-id="tab1fn5" href="#tab1fn5">§</a>
</td>
<td colspan="1" rowspan="1" align="center">406 (73.3)</td>
<td colspan="1" rowspan="1" align="center">1054 (71.0)</td>
<td colspan="1" rowspan="1" align="center">3654 (65.0)</td>
<td colspan="1" rowspan="1" align="center">1541 (62.2)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">History of amputation, No. (%)</td>
<td colspan="1" rowspan="1" align="center">29 (5.2)</td>
<td colspan="1" rowspan="1" align="center">55 (3.7)</td>
<td colspan="1" rowspan="1" align="center">105 (1.9)</td>
<td colspan="1" rowspan="1" align="center">49 (2.0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Body mass index, kg/m<sup>2</sup>, mean (SD)</td>
<td colspan="1" rowspan="1" align="center">32.6 (6.1)</td>
<td colspan="1" rowspan="1" align="center">32.2 (6.0)</td>
<td colspan="1" rowspan="1" align="center">31.9 (5.8)</td>
<td colspan="1" rowspan="1" align="center">31.8 (6.2)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Systolic BP, mm Hg, mean (SD)</td>
<td colspan="1" rowspan="1" align="center">137.4 (17.8)</td>
<td colspan="1" rowspan="1" align="center">137.5 (16.0)</td>
<td colspan="1" rowspan="1" align="center">136.7 (15.5)</td>
<td colspan="1" rowspan="1" align="center">135.7 (15.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Diastolic BP, mm Hg, mean (SD)</td>
<td colspan="1" rowspan="1" align="center">74.1 (10.5)</td>
<td colspan="1" rowspan="1" align="center">76.0 (9.9)</td>
<td colspan="1" rowspan="1" align="center">78.0 (9.5)</td>
<td colspan="1" rowspan="1" align="center">78.8 (9.4)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Glycohemoglobin, %, mean (SD)</td>
<td colspan="1" rowspan="1" align="center">8.3 (1.0)</td>
<td colspan="1" rowspan="1" align="center">8.2 (0.9)</td>
<td colspan="1" rowspan="1" align="center">8.2 (0.9)</td>
<td colspan="1" rowspan="1" align="center">8.3 (0.9)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Total cholesterol, mmol/L, mean (SD)</td>
<td colspan="1" rowspan="1" align="center">4.4 (1.1)</td>
<td colspan="1" rowspan="1" align="center">4.4 (1.2)</td>
<td colspan="1" rowspan="1" align="center">4.3 (1.1)</td>
<td colspan="1" rowspan="1" align="center">4.4 (1.2)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Triglycerides, mmol/L, mean (SD)</td>
<td colspan="1" rowspan="1" align="center">2.2 (1.4)</td>
<td colspan="1" rowspan="1" align="center">2.2 (1.3)</td>
<td colspan="1" rowspan="1" align="center">2.0 (1.3)</td>
<td colspan="1" rowspan="1" align="center">2.0 (1.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">HDL-C, mmol/L, mean (SD)</td>
<td colspan="1" rowspan="1" align="center">1.2 (0.3)</td>
<td colspan="1" rowspan="1" align="center">1.2 (0.3)</td>
<td colspan="1" rowspan="1" align="center">1.2 (0.3)</td>
<td colspan="1" rowspan="1" align="center">1.2 (0.3)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">LDL-C, mmol/L, mean (SD)</td>
<td colspan="1" rowspan="1" align="center">2.2 (0.9)</td>
<td colspan="1" rowspan="1" align="center">2.3 (0.9)</td>
<td colspan="1" rowspan="1" align="center">2.3 (0.9)</td>
<td colspan="1" rowspan="1" align="center">2.4 (0.9)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">LDL-C/HDL-C ratio, mean (SD)</td>
<td colspan="1" rowspan="1" align="center">2.0 (0.9)</td>
<td colspan="1" rowspan="1" align="center">2.1 (0.9)</td>
<td colspan="1" rowspan="1" align="center">2.0 (0.9)</td>
<td colspan="1" rowspan="1" align="center">2.1 (0.9)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">eGFR, mL/min/1.73 m<sup>2</sup>, mean (SD)</td>
<td colspan="1" rowspan="1" align="center">38.2 (5.1)</td>
<td colspan="1" rowspan="1" align="center">53.2 (4.2)</td>
<td colspan="1" rowspan="1" align="center">74.6 (8.3)</td>
<td colspan="1" rowspan="1" align="center">103.2 (13.2)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">UACR, mg/g, median (IQR)</td>
<td colspan="1" rowspan="1" align="center">43.4 (10.3, 310.5)</td>
<td colspan="1" rowspan="1" align="center">17.3 (7.2, 82.1)</td>
<td colspan="1" rowspan="1" align="center">11.2 (6.3, 34.2)</td>
<td colspan="1" rowspan="1" align="center">11.5 (6.8, 31.5)</td>
</tr>
<tr><td colspan="5" rowspan="1" align="left">Albuminuria</td></tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Normoalbuminuria, No. (%)</td>
<td colspan="1" rowspan="1" align="center">241 (44.0)</td>
<td colspan="1" rowspan="1" align="center">888 (60.5)</td>
<td colspan="1" rowspan="1" align="center">4047 (72.8)</td>
<td colspan="1" rowspan="1" align="center">1829 (74.5)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Micro- or macroalbuminuria, No. (%)</td>
<td colspan="1" rowspan="1" align="center">307 (56.0)</td>
<td colspan="1" rowspan="1" align="center">580 (39.5)</td>
<td colspan="1" rowspan="1" align="center">1513 (27.2)</td>
<td colspan="1" rowspan="1" align="center">626 (25.5)</td>
</tr>
</tbody>
</table>
<div class="tableFooter">
<div xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:urlutil="java:com.atypon.literatum.customization.UrlUtil" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="footnote"><p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">BP
 indicates blood pressure; CV, cardiovascular; DPP-4, dipeptidyl 
peptidase-4; eGFR, estimated glomerular filtration rate; GLP-1, 
glucagon-like peptide-1; HDL-C, high-density lipoprotein cholesterol; 
IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol; 
RAAS, renin angiotensin aldosterone system; SD, standard deviation; and 
UACR, urinary albumin/creatinine ratio.</p></div>
<div xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:urlutil="java:com.atypon.literatum.customization.UrlUtil" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="footnote" id="tab1fn2"><p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">*Two
 participants had missing eGFR at baseline and were included in the 
overall trial population but not subgroup analyses by baseline eGFR.</p></div>
<div xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:urlutil="java:com.atypon.literatum.customization.UrlUtil" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="footnote" id="tab1fn3"><p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">†Includes American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, multiple, other, and unknown.</p></div>
<div xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:urlutil="java:com.atypon.literatum.customization.UrlUtil" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="footnote" id="tab1fn4"><p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">‡Some participants had ≥1 type of atherosclerotic disease.</p></div>
<div xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:urlutil="java:com.atypon.literatum.customization.UrlUtil" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="footnote" id="tab1fn5"><p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">§As defined in the protocol.</p></div>
</div>
</div>
<div id="acd3e1759" class="anchor-spacer"></div>
<h4 class="article-section__title" id="d3e1759">Intermediate Outcomes</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Canagliflozin
 significantly reduced HbA1c, systolic blood pressure, body weight, and 
albuminuria compared to placebo in participants across all levels of 
kidney function, although effects on HbA1c were attenuated progressively
 in lower eGFR subgroups (<a data-tab="pane-pcw-Figures" href="#F1" id="F1R" class="">Figure 1</a>).
 The placebo-adjusted mean difference in HbA1c in participants with 
baseline eGFR ≥90, 60 to &lt;90, 45 to &lt;60, and &lt;45 mL/min/1.73 m<sup>2</sup> was −0.76%, −0.57%, −0.45%, and −0.35%, respectively (<i>P</i>
 heterogeneity &lt;0.0001). In contrast, reductions in body weight 
(−2.45, −2.23, −1.95, and −2.30 kg) and blood pressure (−3.92, −4.06, 
−3.66, and −3.29 mm Hg) were similar across the respective eGFR 
subgroups (<i>P</i> heterogeneity = 0.16 and 0.46). The geometric mean 
ratio of UACR compared to placebo was −17%, −17%, −26%, and −13% for the
 same eGFR categories (<i>P</i> heterogeneity = 0.01).</p>
<figure id="F1" class="article__inlineFigure"><img class="figure__image" src="1537fig01.gif" alt="Figure 1."><div class="figure-links"><ul class="rlist--inline">
<li><a href="https://www.ahajournals.org/cms/attachment/5d45ec4e-c341-448d-a653-f8c10323f2e6/1537fig01.gif" download="">Download figure</a></li>
<li><a href="https://www.ahajournals.org/action/downloadFigures?id=F1&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901" class="ppt-figure-link">Download PowerPoint</a></li>
</ul></div>
<figcaption><strong class="figure__title"></strong><span class="figure__caption"><p><strong class="captionLabel">Figure 1.</strong> <strong>Changes
 in intermediate outcomes with canagliflozin compared to placebo in 
participants with eGFR &lt;45, 45 to &lt;60, 60 to &lt;90, and ≥90 
mL/min/1.73 m<sup>2</sup> at baseline.</strong> Represents the mean 
difference in change from baseline between canagliflozin and placebo 
from post-baseline to end of follow-up, except for UACR, where it is 
percent change in the geometric mean of canagliflozin relative to 
placebo. BP indicates blood pressure; eGFR, estimated glomerular 
filtration rate; HbA1c, glycohemoglobin; and UACR, urinary 
albumin/creatinine ratio.</p></span></figcaption></figure><p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">When intermediate outcomes were compared in participants with and without CKD (<a class="references__uri" href="https://www.ahajournals.org/doi/suppl/10.1161/circulationaha.118.035901">Figure I in the online-only Data Supplement</a>),
 similar results were observed; however, the effect of canagliflozin on 
body weight was attenuated in participants with CKD (−1.32 kg versus 
−1.67 kg; <i>P</i> heterogeneity = 0.0002).</p>
<div id="acd3e1809" class="anchor-spacer"></div>
<h4 class="article-section__title" id="d3e1809">Cardiovascular Outcomes</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The effects of canagliflozin on cardiovascular outcomes stratified into 4 eGFR subgroups are summarized in <a data-tab="pane-pcw-Figures" href="#F2" id="F2R" class="">Figure 2</a>. Cardiovascular outcomes in participants with CKD are shown in <a class="references__uri" href="https://www.ahajournals.org/doi/suppl/10.1161/circulationaha.118.035901">Figure II in the online-only Data Supplement</a> and compared to those with preserved kidney function in <a class="references__uri" href="https://www.ahajournals.org/doi/suppl/10.1161/circulationaha.118.035901">Figures III and IV in the online-only Data Supplement</a>.</p>
<figure id="F2" class="article__inlineFigure"><img class="figure__image" src="1537fig02.gif" alt="Figure 2."><div class="figure-links"><ul class="rlist--inline">
<li><a href="https://www.ahajournals.org/cms/attachment/088ea07a-3e02-4c92-9002-4f34fe713b17/1537fig02.gif" download="">Download figure</a></li>
<li><a href="https://www.ahajournals.org/action/downloadFigures?id=F2&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901" class="ppt-figure-link">Download PowerPoint</a></li>
</ul></div>
<figcaption><strong class="figure__title"></strong><span class="figure__caption"><p><strong class="captionLabel">Figure 2.</strong> <strong>Effects
 of canagliflozin on cardiovascular and renal outcomes in participants 
according to baseline eGFR categories &lt;45, 45 to &lt;60, 60 to 
&lt;90, and ≥90 mL/min/1.73 m<sup>2</sup></strong>. CV indicates 
cardiovascular; eGFR, estimated glomerular filtration rate; HF, heart 
failure; HR, hazard ratio; MACE, major adverse cardiovascular event; and
 MI, myocardial infarction. *Renal composite: 40% decrease in eGFR, 
end-stage kidney disease, or renal death.</p></span></figcaption></figure><p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 relative risk reduction in the primary outcome for the overall trial 
population (HR, 0.86; 95% CI, 0.75–0.97) was similar across 4 eGFR 
subgroups and for participants with and without CKD (<i>P</i> 
heterogeneity = 0.33 and 0.08, respectively). Similarly, the effect on 
cardiovascular death (HR, 0.87; 95% CI, 0.72–1.06) was not modified by 
baseline kidney function (<i>P</i> heterogeneity &gt;0.50).</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">While
 overall effects on fatal/nonfatal myocardial infarction (HR, 0.89; 95% 
CI, 0.73–1.09) and hospitalization for heart failure (HR, 0.67; 95% CI, 
0.52–0.87), were consistent across 4 eGFR subgroups (<i>P</i> 
heterogeneity = 0.08 and &gt;0.50, respectively), heterogeneity was 
observed for the effect on fatal/nonfatal stroke (HR, 0.87; 95% CI, 
0.69–1.09), with possibly greater benefits with declining kidney 
function (<i>P</i> heterogeneity = 0.01). The same effect modification was observed for participants with and without CKD (<i>P</i> heterogeneity = 0.01; <a class="references__uri" href="https://www.ahajournals.org/doi/suppl/10.1161/circulationaha.118.035901">Figure IV in the online-only Data Supplement</a>).
 When interaction tests were undertaken using eGFR as a continuous 
variable, heterogeneity was again found for the effect on stroke (<i>P</i> heterogeneity = 0.004), but not any of the other cardiovascular outcomes (all <i>P</i>
 heterogeneity &gt;0.20). Results for all cardiovascular outcomes were 
similar in sensitivity analyses adjusted for competing risk of death.</p>
<div id="acd3e1873" class="anchor-spacer"></div>
<h4 class="article-section__title" id="d3e1873">Renal Outcomes</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 reduction in risk of progression to the adjudicated renal composite 
outcome of sustained 40% decrease in eGFR, end-stage kidney disease, or 
renal death with canagliflozin in the overall trial population (HR, 
0.60; 95% CI, 0.47–0.77) was consistent across 2 and 4 eGFR subgroups (<i>P</i>
 heterogeneity = 0.28 and &gt;0.50, respectively), and when doubling of 
serum creatinine was substituted for 40% decrease in eGFR in the renal 
composite (HR, 0.53; 95% CI, 0.33–0.84 for all participants; <i>P</i> 
heterogeneity = 0.21 and &gt;0.50, respectively). When interaction tests
 were undertaken using eGFR as a continuous variable, the renoprotective
 effect of canagliflozin (for both 40% decrease in eGFR and doubling of 
serum creatinine–based composite outcomes) continued to suggest benefit 
at all levels of kidney function, but may be attenuated with declining 
kidney function (<i>P</i> heterogeneity = 0.02 and 0.01, respectively). 
Effects on the composite renal outcomes were similar in sensitivity 
analyses adjusting for competing risk of death.</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 difference in eGFR slope between canagliflozin and placebo arms varied 
during follow-up. Within the first 13 weeks, participants who received 
canagliflozin experienced a decline in eGFR, which was similar in 
participants with eGFR ≥90, 60 to &lt;90, 45 to &lt;60, and &lt;45 
mL/min/1.73 m<sup>2</sup> at baseline (placebo-subtracted differences of −1.89, −2.33, −2.85, and −2.75 mL/min/1.73 m<sup>2</sup>, respectively; <i>P</i>
 heterogeneity = 0.09). From week 13 to the end of follow-up (ie, the 
chronic eGFR slope), canagliflozin significantly slowed the annual 
decline in kidney function in all subgroups (<a data-tab="pane-pcw-Figures" href="#F3" id="F3R" class="">Figure 3</a>), with placebo-subtracted mean slope differences of 1.47, 1.09, 1.05, and 1.35 mL/min/1.73 m<sup>2</sup> per year for respective eGFR subgroups (<i>P</i>
 heterogeneity = 0.21). The overall eGFR slope during follow-up for 
canagliflozin- and placebo-treated participants in each eGFR subgroup is
 shown in <a class="references__uri" href="https://www.ahajournals.org/doi/suppl/10.1161/circulationaha.118.035901">Figure V in the online-only Data Supplement</a>.
 In participants who were re-evaluated approximately 30 days after 
treatment discontinuation (as part of the CANVAS-R protocol), the 
differences in change from baseline to off-treatment eGFR levels between
 canagliflozin and placebo arms across 2 and 4 eGFR subgroups are 
summarized <a class="references__uri" href="https://www.ahajournals.org/doi/suppl/10.1161/circulationaha.118.035901">Figures VI and VII in the online-only Data Supplement</a>, respectively.</p>
<figure id="F3" class="article__inlineFigure"><img class="figure__image" src="1537fig03.gif" alt="Figure 3."><div class="figure-links"><ul class="rlist--inline">
<li><a href="https://www.ahajournals.org/cms/attachment/d74269ac-cc8c-47c4-a112-794ea9e57381/1537fig03.gif" download="">Download figure</a></li>
<li><a href="https://www.ahajournals.org/action/downloadFigures?id=F3&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901" class="ppt-figure-link">Download PowerPoint</a></li>
</ul></div>
<figcaption><strong class="figure__title"></strong><span class="figure__caption"><p><strong class="captionLabel">Figure 3.</strong> <strong>Effect
 on eGFR slope from week 6/13 until end of follow-up in participants 
with eGFR &lt;45, 45 to &lt;60, 60 to &lt;90, and ≥90 mL/min/1.73 m<sup>2</sup> at baseline.</strong>
 eGFR indicates estimated glomerular filtration rate; and SE, standard 
error. *Data are mean±SE. †Data are reported for week 6 in CANVAS and 
week 13 in CANVAS-R.</p></span></figcaption></figure><div id="acd3e1935" class="anchor-spacer"></div>
<h4 class="article-section__title" id="d3e1935">Adverse Outcomes</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Effects of canagliflozin on safety outcomes were consistent across eGFR subgroups, including for serious renal safety outcomes (<a data-tab="pane-pcw-Figures" href="#F4" id="F4R" class="">Figures 4</a> and <a data-tab="pane-pcw-Figures" href="#F5" id="F5R" class="">5</a>). The exception was a borderline significant interaction test observed for hypoglycemia across 4 eGFR subgroups (<i>P</i> heterogeneity = 0.06), which persisted when assessed using eGFR as a continuous variable (<i>P</i>
 heterogeneity = 0.004), although participants were more likely to be 
receiving concomitant insulin therapy as kidney function declined. 
Relative effects on other safety outcomes were broadly consistent when 
interaction tests were applied across 4 eGFR subgroups or were 
undertaken using eGFR as a continuous variable.</p>
<figure id="F4" class="article__inlineFigure"><img class="figure__image" src="1537fig04.gif" alt="Figure 4."><div class="figure-links"><ul class="rlist--inline">
<li><a href="https://www.ahajournals.org/cms/attachment/ffafc528-187c-4399-8940-c33bbb627df8/1537fig04.gif" download="">Download figure</a></li>
<li><a href="https://www.ahajournals.org/action/downloadFigures?id=F4&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901" class="ppt-figure-link">Download PowerPoint</a></li>
</ul></div>
<figcaption><strong class="figure__title"></strong><span class="figure__caption"><p><strong class="captionLabel">Figure 4.</strong> <strong>Adverse events across the CANVAS Program in participants with eGFR &lt;45, 45 to &lt;60, 60 to &lt;90, and ≥90 mL/min/1.73 m<sup>2</sup> at baseline.</strong> eGFR indicates estimated glomerular filtration rate; and HR, hazard ratio.</p></span></figcaption></figure><div id="acd3e1972" class="anchor-spacer"></div>
<h4 class="article-section__title" id="d3e1972">Absolute Risk Reduction</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 absolute differences in risk between canagliflozin and placebo across 4
 eGFR subgroups and among participants with and without CKD are shown in
 <a data-tab="pane-pcw-Figures" href="#F6" id="F6R" class="">Figure 6</a> and <a class="references__uri" href="https://www.ahajournals.org/doi/suppl/10.1161/circulationaha.118.035901">Figure VIII in the online-only Data Supplement</a>.
 Absolute effects were consistent across 4 eGFR subgroups, with the 
exception of a borderline possibly greater absolute reduction in risk of
 hospitalization for heart failure with declining kidney function (<i>P</i> heterogeneity = 0.06; <a data-tab="pane-pcw-Figures" href="#F6" id="F6R" class="">Figure 6</a>).
 Similar possible heterogeneity for the absolute effect on heart failure
 was also observed when comparing participants with and without CKD (<i>P</i> heterogeneity = 0.02; <a class="references__uri" href="https://www.ahajournals.org/doi/suppl/10.1161/circulationaha.118.035901">Figure VIII in the online-only Data Supplement</a>).</p>
<figure id="F6" class="article__inlineFigure"><img class="figure__image" src="1537fig05.gif" alt="Figure 6."><div class="figure-links"><ul class="rlist--inline">
<li><a href="https://www.ahajournals.org/cms/attachment/16556279-c90d-491d-8d28-0389373a712b/1537fig05.gif" download="">Download figure</a></li>
<li><a href="https://www.ahajournals.org/action/downloadFigures?id=F6&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901" class="ppt-figure-link">Download PowerPoint</a></li>
</ul></div>
<figcaption><strong class="figure__title"></strong><span class="figure__caption"><p><strong class="captionLabel">Figure 6.</strong> <strong>Absolute
 benefits and risks per 1000 patients over 5 years with canagliflozin 
versus placebo in the overall population and in participants with eGFR 
&lt;45, 45 to &lt;60, 60 to &lt;90, and ≥90 mL/min/1.73 m<sup>2</sup> at baseline.</strong>
 eGFR indicates estimated glomerular filtration rate; HF, heart failure;
 and MACE, major adverse cardiovascular event. *Excess number is 
relative to the placebo group. If the number is negative, then fewer 
participants in the canagliflozin group experienced the event compared 
to the placebo group. †Renal composite: 40% decrease in eGFR, end-stage 
kidney disease, or renal death.</p></span></figcaption></figure><div id="acd3e2017" class="anchor-spacer"></div>
<h3 class="article-section__title to-section " id="d3e2017">Discussion</h3>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">In
 this secondary analysis of the CANVAS Program, the relative effects of 
canagliflozin on the primary and most other cardiovascular outcomes were
 consistent across different levels of kidney function with possibly 
heterogeneity observed only for the outcome of fatal/nonfatal stroke. 
Absolute effects were also similar, with the exception of a possibly 
greater absolute benefit with respect to heart failure across 
progressively lower eGFR subgroups. These data also suggest the 
renoprotective effects of canagliflozin are not likely to be modified by
 baseline eGFR, with slower rates of kidney function loss at all levels 
of baseline kidney function and similar effects on the composite renal 
outcomes in all eGFR strata, while also raising the possibility that the
 magnitude of benefit might be somewhat attenuated in participants with 
lower baseline eGFR levels. Taken together, these data suggest that the 
cardiovascular and renal effects of canagliflozin are consistent across 
different levels of kidney function in people with type 2 diabetes with 
or at high risk of cardiovascular disease down to eGFR levels of 30 
mL/min/1.73 m<sup>2</sup>.</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">One
 of the hallmark characteristics of this class of agents is their lesser
 effect on urinary glucose excretion with decreasing kidney function,<sup><a data-tab="pane-pcw-references" href="#R16" id="R16R" class="tab-link">16</a>,<a data-tab="pane-pcw-references" href="#R17" id="R17R" class="tab-link">17</a></sup> which has been demonstrated with a number of agents in the class,<sup><a data-tab="pane-pcw-references" href="#R8" id="R8R" class="tab-link">8</a>,<a data-tab="pane-pcw-references" href="#R18" id="R18R" class="tab-link">18</a>,<a data-tab="pane-pcw-references" href="#R19" id="R19R" class="tab-link">19</a></sup>
 and is likely to be mediated by reduced available nephron mass, and 
therefore, diminished glucose reabsorption capacity. In contrast, while 
effects on sodium reabsorption and natriuresis are equally likely to be 
dependent on kidney function, the blood pressure–lowering effects of 
canagliflozin were similar across eGFR subgroups. A synergistic 
hemodynamic effect with other blood pressure–lowering agents or 
diuretics could potentially explain these findings, given that 
participants were more likely to be taking these drugs in progressively 
lower eGFR categories. Another possibility may be that patients with CKD
 exhibit higher sensitivity to changes in renal sodium and glucose 
handling,<sup><a data-tab="pane-pcw-references" href="#R8" id="R8R" class="tab-link">8</a></sup>
 or that there are other as yet unrecognized mechanisms involved. The 
variations in UACR reduction across eGFR subgroups were not explained by
 the use of RAS blockade, which was similar at baseline and during 
follow-up for the canagliflozin and placebo arms across all levels of 
kidney function, highlighting the need for further mechanistic insights 
into SGLT2 inhibition.</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 reason that the relative cardiovascular benefits are at least as large 
in participants with CKD is therefore unclear, and the results of this 
analysis require confirmation and clarification in dedicated, separately
 powered trials in people with diabetic kidney disease. Our findings are
 broadly consistent with a similar analysis of empagliflozin.<sup><a data-tab="pane-pcw-references" href="#R18" id="R18R" class="tab-link">18</a></sup>
 While it is unclear why treatment heterogeneity was observed for the 
outcome of stroke, qualitatively similar findings have been reported 
with empagliflozin,<sup><a data-tab="pane-pcw-references" href="#R18" id="R18R" class="tab-link">18</a></sup>
 supporting the need for better understanding of this finding. Given the
 attenuated effect on HbA1c in patients with CKD, as well as the 
inconsistent evidence for glucose lowering for the prevention of 
macrovascular complications in type 2 diabetes,<sup><a data-tab="pane-pcw-references" href="#R20%20R21%20R22" id="R20 R21 R22R" class="tab-link">20–22</a></sup>
 these data suggest that the cardiovascular benefits in patients with 
CKD are not likely to be driven by glucose excretion alone.<sup><a data-tab="pane-pcw-references" href="#R22" id="R22R" class="tab-link">22</a></sup>
 The preserved blood pressure–lowering effect in this population 
highlights sodium and volume overload as critical contributors to the 
increased cardiovascular and renal burden in people with CKD.<sup><a data-tab="pane-pcw-references" href="#R23" id="R23R" class="tab-link">23</a></sup>
 Other mechanisms may also contribute; for example, there is evidence 
that SGLT2 inhibition modestly increases the production of circulating 
ketones, thus providing an alternative energy substrate that might 
improve myocardial cell function in the setting of hypoxic or ischemic 
stress.<sup><a data-tab="pane-pcw-references" href="#R22" id="R22R" class="tab-link">22</a>,<a data-tab="pane-pcw-references" href="#R24%20R25%20R26" id="R24 R25 R26R" class="tab-link">24–26</a></sup>
 The strength of these findings is supported by the consistency of the 
results when eGFR is further subdivided into a greater number of 
categories and analyzed as a continuous variable.</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">It
 is likely that SGLT2 inhibitors confer kidney benefits through a direct
 renal mechanism. Head-to-head trials with other glucose-lowering agents
 have shown that canagliflozin slows decline in kidney function 
independent of glycemic control.<sup><a data-tab="pane-pcw-references" href="#R19" id="R19R" class="tab-link">19</a></sup>
 An increasingly cited physiological explanation for the renoprotective 
properties of this class of agents is their ability to enhance afferent 
arteriolar tone by manipulating tubuloglomerular feedback,<sup><a data-tab="pane-pcw-references" href="#R3" id="R3R" class="tab-link">3</a></sup> thereby reducing intraglomerular pressure via mechanisms that parallel and are complementary to those of RAS blockade.<sup><a data-tab="pane-pcw-references" href="#R27" id="R27R" class="tab-link">27</a></sup>
 Clinically this is reflected in the acute dose-dependent decline in 
eGFR on initiation of SGLT2 inhibition, followed by stabilization and 
preservation of kidney function, which has been demonstrated in trials 
of this and other agents in the class.<sup><a data-tab="pane-pcw-references" href="#R6" id="R6R" class="tab-link">6</a>,<a data-tab="pane-pcw-references" href="#R15" id="R15R" class="tab-link">15</a></sup>
 The data from this analysis suggest that these effects on renal 
hemodynamics (as measured by changes in albuminuria and eGFR), and the 
likely kidney protection that results, might be similar across different
 levels of kidney function. The ongoing CREDENCE trial (NCT02065791) 
will specifically study the effects of SGLT2 inhibition in 4401 
participants with established kidney disease and macroalbuminuria, 
almost 60% of whom have eGFR &lt;60 mL/min/1.73 m<sup>2</sup> at baseline, and will provide additional data in this regard.<sup><a data-tab="pane-pcw-references" href="#R28" id="R28R" class="tab-link">28</a></sup>
 Other dedicated CKD outcome trials for empagliflozin (EMPA-KIDNEY) and 
dapagliflozin (DAPA-CKD) have also been announced or are underway.<sup><a data-tab="pane-pcw-references" href="#R29" id="R29R" class="tab-link">29</a>,<a data-tab="pane-pcw-references" href="#R30" id="R30R" class="tab-link">30</a></sup>
 Given the unique renal hemodynamic effects of SGLT2 inhibition, there 
is considerable interest as to whether the potential benefits may extend
 to CKD patients without diabetes. As such, both trials aim to recruit 
patients with and without diabetes, and will be powered to detect 
benefits in the nondiabetic cohort.</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Across
 all outcomes, event rates increased with declining kidney function, 
underscoring the fact that CKD is a cause, consequence, and risk 
multiplier of cardiovascular disease.<sup><a data-tab="pane-pcw-references" href="#R31" id="R31R" class="tab-link">31</a>,<a data-tab="pane-pcw-references" href="#R32" id="R32R" class="tab-link">32</a></sup>
 The absolute risk reductions in these outcomes among participants with 
CKD tended to be larger than those observed in the overall trial 
population and are likely to be greater than the increase in risk of 
amputations, especially major amputations. These benefits are also 
likely to be clinically important, especially as they occurred in 
addition to the standard of care that included RAS blockade in 
approximately 80% of participants. Importantly, there appears to be no 
increased risk of renal adverse events, including acute kidney injury or
 hyperkalemia, when SGLT2 inhibitors are used in combination with RAS 
blockade in participants with CKD, including those with eGFR between 30 
and 45 mL/min/1.73 m<sup>2</sup>.</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">This
 study has a number of strengths. Data were derived from a large, 
multicenter, placebo-controlled trial program that was conducted to an 
extremely high standard. The cardiovascular and renal outcomes are 
clinically meaningful and were adjudicated by expert committees. While 
not explicitly powered to assess results in participants with 
established kidney disease, this represents one of the largest analyses 
to date of the effects of SGLT2 inhibition on cardiovascular and renal 
outcomes in this high cardiovascular and renal risk population.</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">This
 secondary analysis of the CANVAS Program is limited by drawbacks 
inherent to all post hoc analyses of randomized trials. The interaction <i>P</i>
 values reported for eGFR subgroups are nominal in nature, and no 
correction was applied for multiple comparisons. The relatively small 
number of participants with eGFR &lt;45 mL/min/1.73 m<sup>2</sup> 
precludes our ability to draw definitive conclusions about the effects 
of canagliflozin in participants with significantly reduced kidney 
function, but underscores the importance of CREDENCE and other planned 
or ongoing CKD outcome trials for dapagliflozin and empagliflozin.<sup><a data-tab="pane-pcw-references" href="#R29" id="R29R" class="tab-link">29</a>,<a data-tab="pane-pcw-references" href="#R30" id="R30R" class="tab-link">30</a></sup>
 The high proportion of participants with a history of cardiovascular 
disease limits the generalizability of these findings to the broader CKD
 population. However, the magnitude and consistency of effect size on a 
range of outcomes, as well as concordance with subgroup data from the 
EMPA-REG OUTCOME trial, support the likely beneficial effects of SGLT2 
inhibitors in high cardiovascular risk patients with type 2 diabetes and
 eGFR levels down to 30 mL/min/1.73 m<sup>2</sup>. The number of events 
for some outcomes, particularly progression to end-stage kidney disease,
 were too few to draw definitive conclusions. Finally, participants with
 an eGFR below 30 mL/min/1.73 m<sup>2</sup> were excluded, so the effects in this population remain to be determined.</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">In
 conclusion, despite smaller effects on HbA1c with declining kidney 
function, the effects of canagliflozin on cardiovascular and renal 
outcomes were not modified by baseline eGFR in people with type 2 
diabetes and a history or high risk of cardiovascular disease. 
Reassessing current limitations on the use of canagliflozin in CKD may 
allow additional individuals to benefit from this therapy.</p>
<figure id="F5" class="article__inlineFigure"><img class="figure__image" src="1537fig06.gif" alt="Figure 5."><div class="figure-links"><ul class="rlist--inline">
<li><a href="https://www.ahajournals.org/cms/attachment/8fa96603-8cf6-4418-992b-825ff4cd9aea/1537fig06.gif" download="">Download figure</a></li>
<li><a href="https://www.ahajournals.org/action/downloadFigures?id=F5&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901" class="ppt-figure-link">Download PowerPoint</a></li>
</ul></div>
<figcaption><strong class="figure__title"></strong><span class="figure__caption"><p><strong class="captionLabel">Figure 5.</strong> <strong>Adverse events collected in CANVAS alone in participants with eGFR ≤45, 45 to &lt;60, 60 to &lt;90, and ≥90 mL/min/1.73 m<sup>2</sup> at baseline.</strong>
 The annualized incidence rates, estimates for HRs, and 95% CIs are 
reported for the CANVAS study alone through January 7, 2014, because 
after this time, only serious adverse events or adverse events leading 
to study drug discontinuation, or selected adverse events of interest 
were collected. eGFR indicates estimated glomerular filtration rate; and
 HR, hazard ratio. *Note that 1 patient in the placebo group who 
experienced an event had a missing baseline eGFR value; therefore, this 
patient is only counted in the overall total. †Data collected in CANVAS 
and CANVAS-R. Includes infections of male genitalia and phimosis and 
excludes circumcision.</p></span></figcaption></figure><div id="acd3e2181" class="anchor-spacer"></div>
<h3 class="article-section__title to-section " id="d3e2181">Acknowledgments</h3>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 paper is presented on behalf of the CANVAS Program collaborative group.
 The authors thank all investigators, study teams, and patients for 
participating in these studies. The authors thank the following 
individuals for their contributions to the statistical 
monitoring/analyses and the protocol development, safety monitoring, and
 operational implementation over the duration of both studies: Lyndal 
Hones, Sharon Dunkley, Tao Sun, Gordon Law, George Capuano, Severine 
Bompoint, Laurent Billot, Mary Lee, Joan Lind, Roger Simpson, Mary 
Kavalam, Ed Connell, Jacqueline Yee, Dainius Balis, Frank Vercruysse, 
Elisa Fabbrini, Richard Oh, Nicole Meyers, Wayne Shaw, and Gary 
Meininger. B.L.N., T.O., H.D., and Q.L. contributed to the analysis and 
interpretation of data. B.N., D.R.M., D.d.Z., K.W.M., G.F., M.D., N.R., 
M.J.J., G.B., and V.P. contributed to the design and conduct of the 
study and the interpretation of the data. B.L.N. and V.P. wrote the 
first draft of the manuscript, and all authors contributed to subsequent
 drafts and approved the final version for submission. V.P. and M.D. are
 the guarantors of this work and, as such, had full access to all the 
data in the study and take responsibility for the integrity of the data 
and the accuracy of the data analysis.</p>
<div class="articleInformation">
<div id="acd3e2189" class="anchor-spacer"></div>
<h3 class="article-section__title to-section " id="d3e2189">Sources of Funding</h3>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">This
 work was supported by Janssen Research &amp; Development, LLC. The 
sponsor was involved in the design and conduct of the study; collection,
 management, analysis, and interpretation of the data; preparation, 
review, or approval of the manuscript; and the decision to submit the 
manuscript for publication. Medical writing support was provided by 
Kimberly Dittmar, PhD, of MedErgy, and was funded by Janssen Global 
Services, LLC. Canagliflozin has been developed by Janssen Research 
&amp; Development, LLC, in collaboration with Mitsubishi Tanabe Pharma 
Corp.</p>
</div>
<div class="articleInformation">
<div id="acd3e2197" class="anchor-spacer"></div>
<h3 class="article-section__title to-section " id="d3e2197">Disclosures</h3>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Dr
 Neuen is supported by the John Chalmers PhD Scholarship from The George
 Institute for Global Health and a University Postgraduate Award from 
University of New South Wales Sydney. Dr Ohkuma is supported by the John
 Chalmers Clinical Research Fellowship of the George Institute. Q. Li 
reports being full-time employees of The George Institute for Global 
Health. Dr Neal has received research support from the Australian 
National Health and Medical Research Council Principal Research 
Fellowship and from Janssen, Roche, Servier, and Merck Schering-Plough; 
and has served on advisory boards and/or has been involved in continuing
 medical education programs for Abbott, Janssen, Novartis, Pfizer, 
Roche, and Servier, with any consultancy, honoraria, or travel support 
paid to his institution. Dr Matthews has received research support from 
Janssen; served on advisory boards and as a consultant for Novo Nordisk,
 Novartis, Sanofi-Aventis, Janssen, and Servier; and has given lectures 
for Novo Nordisk, Servier, Sanofi-Aventis, Novartis, Janssen, Mitsubishi
 Tanabe, and Aché Laboratories. Dr de Zeeuw has served on advisory 
boards and/or as a speaker for AbbVie, Astellas, Fresenius, Janssen, 
Boehringer Ingelheim, Bayer, and Mitsubishi Tanabe, with all consultancy
 honoraria paid to his institution. Dr Mahaffey’s disclosures can be 
viewed at <a class="references__uri" href="http://med.stanford.edu/profiles/kenneth-mahaffey">http://med.stanford.edu/profiles/kenneth-mahaffey</a>.
 Dr Fulcher has received research support from Novo Nordisk, and served 
on advisory boards and as a consultant for Janssen, Novo Nordisk, 
Boehringer Ingelheim, and Merck Sharp &amp; Dohme. Drs Desai and 
Rosenthal and H. Deng are full-time employees of Janssen Research &amp; 
Development, LLC, and hold stock in Johnson &amp; Johnson. Dr Jardine is
 supported by a Medical Research Future Fund Next Generation Clinical 
Researchers Program Career Development Fellowship; is responsible for 
research projects that have received unrestricted funding from Gambro, 
Baxter, CSL, Amgen, Eli Lilly, and Merck; has served on advisory boards 
sponsored by Akebia, Baxter, and Boehringer Ingelheim; and has spoken at
 scientific meetings sponsored by Janssen, Amgen, and Roche with any 
consultancy, honoraria, or travel support paid to her institution. Dr 
Bakris has received research funding paid to the University of Chicago 
for Bayer, Janssen, and Vascular Dynamics; has served as a consultant 
for Merck and Relypsa; and has served as Editor-in-Chief for <i>American Journal of Nephrology</i>, as the Nephrology and Hypertension Section Editor for <i>UpToDate</i>, as Section Editor of<i>Hypertension</i>, and as associate editor of <i>Diabetes Care</i> and <i>Hypertension Research</i>.
 Dr Perkovic has received research support from the Australian National 
Health and Medical Research Council (Senior Research Fellowship and 
Program Grant); served on Steering Committees for AbbVie, Boehringer 
Ingelheim, GlaxoSmithKline, Janssen, and Pfizer; and served on advisory 
boards and/or spoken at scientific meetings for AbbVie, Astellas, 
AstraZeneca, Bayer, Baxter, Bristol-Myers Squibb, Boehringer Ingelheim, 
Durect, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, 
Novo Nordisk, Pfizer, Pharmalink, Relypsa, Roche, Sanofi, Servier, and 
Vitae, with all honoraria paid to his employer.</p>
</div>
<h3 class="article-section__title to-section " id="d2856604e258">Footnotes</h3>
<div class="NLM_author-notes">
<fn xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" fn-type="financial-disclosure" id="fn01"><p>Sources of Funding, see page 1549</p></fn><fn xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" fn-type="supplementary-material" id="fn02"><p>The online-only Data Supplement is available with this article at <a class="references__uri" href="https://www.ahajournals.org/doi/suppl/10.1161/circulationaha.118.035901">https://www.ahajournals.org/doi/suppl/10.1161/circulationaha.118.035901</a>.</p></fn><fn xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" fn-type="other" id="fn03"><p><a class="references__uri" href="https://www.ahajournals.org/journal/circ">https://www.ahajournals.org/journal/circ</a></p></fn><div class="NLM_corresp">Vlado
 Perkovic, MBBS, PhD, The George Institute for Global Health, UNSW 
Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW 2050 
Australia 2050. Email <a class="references__email" href="mailto:vperkovic@georgeinstitute.org.au"><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:urlutil="java:com.atypon.literatum.customization.UrlUtil" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="nobrWithWbr">vperkovic@georgeinstitute.<wbr xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">org.<wbr xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">au</wbr></wbr></span></a>
</div>
</div>
<div class="article__references">
<p class="explanation__text"></p>
<h2 class="article-section__title to-section" id="d2856604e1610">References</h2>
<ul class="rlist separator">
<li id="R1" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R1R" class="tab-link-return ref__number"><span class="label">1. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Sarwar
 N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson
 E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells
 L, Thompson A, Sattar N, White IR, Ray KK and Danesh J</person-group>. <span class="references__article-title">Diabetes
 mellitus, fasting blood glucose concentration, and risk of vascular 
disease: a collaborative meta-analysis of 102 prospective studies.</span><span class="references__source"><strong>Lancet</strong></span>. <span class="references__year">2010</span>; 375:2215–2222. doi 10.1016/S0140-6736(10)60484–9<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_2_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=10.1016%2FS0140-6736%2810%2960484-9" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_2_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=20609967" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=375&amp;publication_year=2010&amp;pages=2215-2222&amp;journal=Lancet&amp;author=N+Sarwar&amp;author=P+Gao&amp;author=SR+Seshasai&amp;author=R+Gobin&amp;author=S+Kaptoge&amp;author=E+Di+Angelantonio&amp;author=E+Ingelsson&amp;author=DA+Lawlor&amp;author=E+Selvin&amp;author=M+Stampfer&amp;author=CD+Stehouwer&amp;author=S+Lewington&amp;author=L+Pennells&amp;author=A+Thompson&amp;author=N+Sattar&amp;author=IR+White&amp;author=KK+Ray&amp;author=J+Danesh&amp;title=Diabetes+mellitus%2C+fasting+blood+glucose+concentration%2C+and+risk+of+vascular+disease%3A+a+collaborative+meta-analysis+of+102+prospective+studies." target="_blank">Google Scholar</a></span></span></li>
<li id="R2" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R2R" class="tab-link-return ref__number"><span class="label">2. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, de Boer IH</person-group>. <span class="references__article-title">Kidney disease and increased mortality risk in type 2 diabetes.</span><span class="references__source"><strong>J Am Soc Nephrol</strong></span>. <span class="references__year">2013</span>; 24:302–308. doi: 10.1681/ASN.2012070718<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_3_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=10.1681%2FASN.2012070718" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_3_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=23362314" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=24&amp;publication_year=2013&amp;pages=302-308&amp;journal=J+Am+Soc+Nephrol&amp;author=M+Afkarian&amp;author=MC+Sachs&amp;author=B+Kestenbaum&amp;author=IB+Hirsch&amp;author=KR+Tuttle&amp;author=J+Himmelfarb&amp;author=IH+de+Boer&amp;title=Kidney+disease+and+increased+mortality+risk+in+type+2+diabetes." target="_blank">Google Scholar</a></span></span></li>
<li id="R3" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R3R" class="tab-link-return ref__number"><span class="label">3. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ</person-group>. <span class="references__article-title">Sodium
 glucose cotransporter 2 inhibitors in the treatment of diabetes 
mellitus: cardiovascular and kidney effects, potential mechanisms, and 
clinical applications.</span><span class="references__source"><strong>Circulation</strong></span>. <span class="references__year">2016</span>; 134:752–772. doi: 10.1161/CIRCULATIONAHA.116.021887<span class="references__suffix"><a href="https://www.ahajournals.org/doi/10.1161/circulationaha.116.021887" onclick="newWindow(this.href);return false" target="_blank">Link</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=134&amp;publication_year=2016&amp;pages=752-772&amp;journal=Circulation&amp;author=HJ+Heerspink&amp;author=BA+Perkins&amp;author=DH+Fitchett&amp;author=M+Husain&amp;author=DZ+Cherney&amp;title=Sodium+glucose+cotransporter+2+inhibitors+in+the+treatment+of+diabetes+mellitus%3A+cardiovascular+and+kidney+effects%2C+potential+mechanisms%2C+and+clinical+applications." target="_blank">Google Scholar</a></span></span></li>
<li id="R4" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R4R" class="tab-link-return ref__number"><span class="label">4. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR</person-group>; on behalf of the CANVAS Program Collaborative Group. <span class="references__article-title">Canagliflozin and cardiovascular and renal events in type 2 diabetes.</span><span class="references__source"><strong>N Engl J Med</strong></span>. <span class="references__year">2017</span>; 377:644–657. doi 10.1056/NEJMoa1611925<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_5_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=10.1056%2FNEJMoa1611925" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_5_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=28605608" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=377&amp;publication_year=2017&amp;pages=644-657&amp;journal=N+Engl+J+Med&amp;author=B+Neal&amp;author=V+Perkovic&amp;author=KW+Mahaffey&amp;author=D+de+Zeeuw&amp;author=G+Fulcher&amp;author=N+Erondu&amp;author=W+Shaw&amp;author=G+Law&amp;author=M+Desai&amp;author=DR+Matthews&amp;title=Canagliflozin+and+cardiovascular+and+renal+events+in+type+2+diabetes." target="_blank">Google Scholar</a></span></span></li>
<li id="R5" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R5R" class="tab-link-return ref__number"><span class="label">5. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Zinman
 B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, 
Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE</person-group>; EMPA-REG OUTCOME Investigators. <span class="references__article-title">Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.</span><span class="references__source"><strong>N Engl J Med</strong></span>. <span class="references__year">2015</span>; 373:2117–2128. doi: 10.1056/NEJMoa1504720<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_6_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=10.1056%2FNEJMoa1504720" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_6_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=26378978" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=373&amp;publication_year=2015&amp;pages=2117-2128&amp;journal=N+Engl+J+Med&amp;author=B+Zinman&amp;author=C+Wanner&amp;author=JM+Lachin&amp;author=D+Fitchett&amp;author=E+Bluhmki&amp;author=S+Hantel&amp;author=M+Mattheus&amp;author=T+Devins&amp;author=OE+Johansen&amp;author=HJ+Woerle&amp;author=UC+Broedl&amp;author=SE+Inzucchi&amp;title=Empagliflozin%2C+cardiovascular+outcomes%2C+and+mortality+in+type+2+diabetes." target="_blank">Google Scholar</a></span></span></li>
<li id="R6" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R6R" class="tab-link-return ref__number"><span class="label">6. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC and Zinman B</person-group>. <span class="references__article-title">Empagliflozin and progression of kidney disease in type 2 diabetes.</span><span class="references__source"><strong>N Engl J Med</strong></span>. <span class="references__year">2016</span>; 375:323–334. doi 10.1056/NEJMoa1515920<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_7_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=10.1056%2FNEJMoa1515920" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_7_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=27299675" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=375&amp;publication_year=2016&amp;pages=323-334&amp;journal=N+Engl+J+Med&amp;author=C+Wanner&amp;author=SE+Inzucchi&amp;author=JM+Lachin&amp;author=D+Fitchett&amp;author=M+von+Eynatten&amp;author=M+Mattheus&amp;author=OE+Johansen&amp;author=HJ+Woerle&amp;author=UC+Broedl&amp;author=B+Zinman&amp;title=Empagliflozin+and+progression+of+kidney+disease+in+type+2+diabetes." target="_blank">Google Scholar</a></span></span></li>
<li id="R7" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R7R" class="tab-link-return ref__number"><span class="label">7. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Petrykiv S, Sjostrom CD, Greasley PJ, Xu J, Persson F and Heerspink HJL</person-group>. <span class="references__article-title">Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function.</span><span class="references__source"><strong>Clin J Am Soc Nephrol</strong></span>. <span class="references__year">2017</span>; 12:751–759. doi 10.2215/CJN.10180916<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_8_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=10.2215%2FCJN.10180916" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_8_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=28302903" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=12&amp;publication_year=2017&amp;pages=751-759&amp;journal=Clin+J+Am+Soc+Nephrol&amp;author=S+Petrykiv&amp;author=CD+Sjostrom&amp;author=PJ+Greasley&amp;author=J+Xu&amp;author=F+Persson&amp;author=HJL+Heerspink&amp;title=Differential+effects+of+dapagliflozin+on+cardiovascular+risk+factors+at+varying+degrees+of+renal+function." target="_blank">Google Scholar</a></span></span></li>
<li id="R8" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R8R" class="tab-link-return ref__number"><span class="label">8. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Cherney DZI, Cooper ME, Tikkanen I, Pfarr E, Johansen OE, Woerle HJ, Broedl UC, Lund SS</person-group>. <span class="references__article-title">Pooled
 analysis of Phase III trials indicate contrasting influences of renal 
function on blood pressure, body weight, and HbA1c reductions with 
empagliflozin.</span><span class="references__source"><strong>Kidney Int</strong></span>. <span class="references__year">2018</span>; 93:231–244. doi: 10.1016/j.kint.2017.06.017<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_9_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=10.1016%2Fj.kint.2017.06.017" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_9_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=28860019" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=93&amp;publication_year=2018&amp;pages=231-244&amp;journal=Kidney+Int&amp;author=DZI+Cherney&amp;author=ME+Cooper&amp;author=I+Tikkanen&amp;author=E+Pfarr&amp;author=OE+Johansen&amp;author=HJ+Woerle&amp;author=UC+Broedl&amp;author=SS+Lund&amp;title=Pooled+analysis+of+Phase+III+trials+indicate+contrasting+influences+of+renal+function+on+blood+pressure%2C+body+weight%2C+and+HbA1c+reductions+with+empagliflozin." target="_blank">Google Scholar</a></span></span></li>
<li id="R9" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R9R" class="tab-link-return ref__number"><span class="label">9. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Hinnen D</person-group>. <span class="references__article-title">Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes.</span><span class="references__source"><strong>Ther Adv Endocrinol Metab</strong></span>. <span class="references__year">2015</span>; 6:92–102. doi: 10.1177/2042018815575273<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_10_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=10.1177%2F2042018815575273" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_10_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=26137213" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=6&amp;publication_year=2015&amp;pages=92-102&amp;journal=Ther+Adv+Endocrinol+Metab&amp;author=D+Hinnen&amp;title=Glucuretic+effects+and+renal+safety+of+dapagliflozin+in+patients+with+type+2+diabetes." target="_blank">Google Scholar</a></span></span></li>
<li id="R10" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R10R" class="tab-link-return ref__number"><span class="label">10. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Scheen AJ</person-group>. <span class="references__article-title">Pharmacokinetics,
 pharmacodynamics and clinical use of SGLT2 inhibitors in patients with 
type 2 diabetes mellitus and chronic kidney disease.</span><span class="references__source"><strong>Clin Pharmacokinet</strong></span>. <span class="references__year">2015</span>; 54:691–708. doi: 10.1007/s40262-015-0264-4<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_11_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=10.1007%2Fs40262-015-0264-4" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_11_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=25805666" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=54&amp;publication_year=2015&amp;pages=691-708&amp;journal=Clin+Pharmacokinet&amp;author=AJ+Scheen&amp;title=Pharmacokinetics%2C+pharmacodynamics+and+clinical+use+of+SGLT2+inhibitors+in+patients+with+type+2+diabetes+mellitus+and+chronic+kidney+disease." target="_blank">Google Scholar</a></span></span></li>
<li id="R11" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R11R" class="tab-link-return ref__number"><span class="label">11. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Seidu S, Kunutsor SK, Cos X, Gillani S, Khunti K</person-group>; for and on behalf of Primary Care Diabetes Europe. <span class="references__article-title">SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: a systematic review and meta-analysis.</span><span class="references__source"><strong>Prim Care Diabetes</strong></span>. <span class="references__year">2018</span>; 12:265–283. doi: 10.1016/j.pcd.2018.02.001<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_12_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=10.1016%2Fj.pcd.2018.02.001" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_12_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=29482993" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=12&amp;publication_year=2018&amp;pages=265-283&amp;journal=Prim+Care+Diabetes&amp;author=S+Seidu&amp;author=SK+Kunutsor&amp;author=X+Cos&amp;author=S+Gillani&amp;author=K+Khunti&amp;title=SGLT2+inhibitors+and+renal+outcomes+in+type+2+diabetes+with+or+without+renal+impairment%3A+a+systematic+review+and+meta-analysis." target="_blank">Google Scholar</a></span></span></li>
<li id="R12" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R12R" class="tab-link-return ref__number"><span class="label">12. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY</person-group>. <span class="references__article-title">Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.</span><span class="references__source"><strong>N Engl J Med</strong></span>. <span class="references__year">2004</span>; 351:1296–1305. doi: 10.1056/NEJMoa041031<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_13_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=10.1056%2FNEJMoa041031" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_13_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=15385656" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=351&amp;publication_year=2004&amp;pages=1296-1305&amp;journal=N+Engl+J+Med&amp;author=AS+Go&amp;author=GM+Chertow&amp;author=D+Fan&amp;author=CE+McCulloch&amp;author=CY+Hsu&amp;title=Chronic+kidney+disease+and+the+risks+of+death%2C+cardiovascular+events%2C+and+hospitalization." target="_blank">Google Scholar</a></span></span></li>
<li id="R13" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R13R" class="tab-link-return ref__number"><span class="label">13. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Fine JP and Gray RJ</person-group>. <span class="references__article-title">A proportional hazards model for the subdistribution of a competing risk.</span><span class="references__source"><strong>J Am Stat Assoc</strong></span>. <span class="references__year">1999</span>; 94:496–509. doi 10.1080/01621459.1999.10474144<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_14_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=10.1080%2F01621459.1999.10474144" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=94&amp;publication_year=1999&amp;pages=496-509&amp;journal=J+Am+Stat+Assoc&amp;author=JP+Fine&amp;author=RJ+Gray&amp;title=A+proportional+hazards+model+for+the+subdistribution+of+a+competing+risk." target="_blank">Google Scholar</a></span></span></li>
<li id="R14" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R14R" class="tab-link-return ref__number"><span class="label">14. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Altman DG, Andersen PK</person-group>. <span class="references__article-title">Calculating the number needed to treat for trials where the outcome is time to an event.</span><span class="references__source"><strong>BMJ</strong></span>. <span class="references__year">1999</span>; 319:1492–1495.<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_15_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=10.1136%2Fbmj.319.7223.1492" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_15_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=10582940" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=319&amp;publication_year=1999&amp;pages=1492-1495&amp;journal=BMJ&amp;author=DG+Altman&amp;author=PK+Andersen&amp;title=Calculating+the+number+needed+to+treat+for+trials+where+the+outcome+is+time+to+an+event." target="_blank">Google Scholar</a></span></span></li>
<li id="R15" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R15R" class="tab-link-return ref__number"><span class="label">15. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Perkovic
 V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, Barrett TD, 
Weidner-Wells M, Deng H, Rosenthal N, Desai M, Matthews DR, Neal B</person-group>. <span class="references__article-title">Canagliflozin and renal outcomes in type 2 diabetes: data from the CANVAS randomized clinical trial program.</span><span class="references__source"><strong>Lancet Diabetes Endocrinol</strong></span>. <span class="references__year">2018</span>; In press. doi 10.1016/S2213-8587(18)30141–4<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_16_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=10.1016%2FS2213-8587%2818%2930141-4" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;publication_year=2018&amp;journal=Lancet+Diabetes+Endocrinol&amp;author=V+Perkovic&amp;author=D+de+Zeeuw&amp;author=KW+Mahaffey&amp;author=G+Fulcher&amp;author=N+Erondu&amp;author=W+Shaw&amp;author=TD+Barrett&amp;author=M+Weidner-Wells&amp;author=H+Deng&amp;author=N+Rosenthal&amp;author=M+Desai&amp;author=DR+Matthews&amp;author=B+Neal&amp;title=Canagliflozin+and+renal+outcomes+in+type+2+diabetes%3A+data+from+the+CANVAS+randomized+clinical+trial+program." target="_blank">Google Scholar</a></span></span></li>
<li id="R16" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R16R" class="tab-link-return ref__number"><span class="label">16. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, Shalayda K, Demarest K, Rothenberg P</person-group>. <span class="references__article-title">Canagliflozin,
 a novel inhibitor of sodium glucose co-transporter 2, dose dependently 
reduces calculated renal threshold for glucose excretion and increases 
urinary glucose excretion in healthy subjects.</span><span class="references__source"><strong>Diabetes Obes Metab</strong></span>. <span class="references__year">2011</span>; 13:669–672. doi: 10.1111/j.1463-1326.2011.01406.x<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_17_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=10.1111%2Fj.1463-1326.2011.01406.x" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_17_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=21457428" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=13&amp;publication_year=2011&amp;pages=669-672&amp;journal=Diabetes+Obes+Metab&amp;author=S+Sha&amp;author=D+Devineni&amp;author=A+Ghosh&amp;author=D+Polidori&amp;author=S+Chien&amp;author=D+Wexler&amp;author=K+Shalayda&amp;author=K+Demarest&amp;author=P+Rothenberg&amp;title=Canagliflozin%2C+a+novel+inhibitor+of+sodium+glucose+co-transporter+2%2C+dose+dependently+reduces+calculated+renal+threshold+for+glucose+excretion+and+increases+urinary+glucose+excretion+in+healthy+subjects." target="_blank">Google Scholar</a></span></span></li>
<li id="R17" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R17R" class="tab-link-return ref__number"><span class="label">17. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Liang
 Y, Arakawa K, Ueta K, Matsushita Y, Kuriyama C, Martin T, Du F, Liu Y, 
Xu J, Conway B, Conway J, Polidori D, Ways K and Demarest K</person-group>. <span class="references__article-title">Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models.</span><span class="references__source"><strong>PLoS ONE</strong></span>. <span class="references__year">2012</span>; 7:e30555. doi 10.1371/journal.pone.0030555<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_18_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=10.1371%2Fjournal.pone.0030555" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_18_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=22355316" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=7&amp;publication_year=2012&amp;pages=e30555&amp;journal=PLoS+ONE&amp;author=Y+Liang&amp;author=K+Arakawa&amp;author=K+Ueta&amp;author=Y+Matsushita&amp;author=C+Kuriyama&amp;author=T+Martin&amp;author=F+Du&amp;author=Y+Liu&amp;author=J+Xu&amp;author=B+Conway&amp;author=J+Conway&amp;author=D+Polidori&amp;author=K+Ways&amp;author=K+Demarest&amp;title=Effect+of+canagliflozin+on+renal+threshold+for+glucose%2C+glycemia%2C+and+body+weight+in+normal+and+diabetic+animal+models." target="_blank">Google Scholar</a></span></span></li>
<li id="R18" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R18R" class="tab-link-return ref__number"><span class="label">18. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, Woerle HJ, Broedl UC, von Eynatten M, Zinman B</person-group>; EMPA-REG OUTCOME Investigators. <span class="references__article-title">Empagliflozin
 and clinical outcomes in patients with type 2 diabetes mellitus, 
established cardiovascular disease, and chronic kidney disease.</span><span class="references__source"><strong>Circulation</strong></span>. <span class="references__year">2018</span>; 137:119–129. doi: 10.1161/CIRCULATIONAHA.117.028268<span class="references__suffix"><a href="https://www.ahajournals.org/doi/10.1161/circulationaha.117.028268" onclick="newWindow(this.href);return false" target="_blank">Link</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=137&amp;publication_year=2018&amp;pages=119-129&amp;journal=Circulation&amp;author=C+Wanner&amp;author=JM+Lachin&amp;author=SE+Inzucchi&amp;author=D+Fitchett&amp;author=M+Mattheus&amp;author=J+George&amp;author=HJ+Woerle&amp;author=UC+Broedl&amp;author=M+von+Eynatten&amp;author=B+Zinman&amp;title=Empagliflozin+and+clinical+outcomes+in+patients+with+type+2+diabetes+mellitus%2C+established+cardiovascular+disease%2C+and+chronic+kidney+disease." target="_blank">Google Scholar</a></span></span></li>
<li id="R19" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R19R" class="tab-link-return ref__number"><span class="label">19. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Heerspink HJ, Desai M, Jardine M, Balis D, Meininger G, Perkovic V</person-group>. <span class="references__article-title">Canagliflozin slows progression of renal function decline independently of glycemic effects.</span><span class="references__source"><strong>J Am Soc Nephrol</strong></span>. <span class="references__year">2017</span>; 28:368–375. doi: 10.1681/ASN.2016030278<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_20_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=10.1681%2FASN.2016030278" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_20_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=27539604" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=28&amp;publication_year=2017&amp;pages=368-375&amp;journal=J+Am+Soc+Nephrol&amp;author=HJ+Heerspink&amp;author=M+Desai&amp;author=M+Jardine&amp;author=D+Balis&amp;author=G+Meininger&amp;author=V+Perkovic&amp;title=Canagliflozin+slows+progression+of+renal+function+decline+independently+of+glycemic+effects." target="_blank">Google Scholar</a></span></span></li>
<li id="R20" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R20R" class="tab-link-return ref__number"><span class="label">20. </span></a>Action to Control Cardiovascular Risk in Diabetes Study Group, <person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Gerstein
 HC, Miller ME, Byington RP, Goff DC., Bigger JT, Buse JB, Cushman WC, 
Genuth S, Ismail-Beigi F, Grimm RH., Probstfield JL, Simons-Morton DG, 
Friedewald WT</person-group>. <span class="references__article-title">Effects of intensive glucose lowering in type 2 diabetes.</span><span class="references__source"><strong>N Engl J Med</strong></span>. <span class="references__year">2008</span>; 358:2545–2559. doi 10.1056/NEJMoa0802743<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_21_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=10.1056%2FNEJMoa0802743" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_21_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=18539917" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=358&amp;publication_year=2008&amp;pages=2545-2559&amp;journal=N+Engl+J+Med&amp;author=HC+Gerstein&amp;author=ME+Miller&amp;author=RP+Byington&amp;author=DC+Goff&amp;author=JT+Bigger&amp;author=JB+Buse&amp;author=WC+Cushman&amp;author=S+Genuth&amp;author=F+Ismail-Beigi&amp;author=RH+Grimm&amp;author=JL+Probstfield&amp;author=DG+Simons-Morton&amp;author=WT+Friedewald&amp;title=Effects+of+intensive+glucose+lowering+in+type+2+diabetes." target="_blank">Google Scholar</a></span></span></li>
<li id="R21" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R21R" class="tab-link-return ref__number"><span class="label">21. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Duckworth
 W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks 
J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, 
Henderson WG, Huang GD</person-group>; VADT Investigators. <span class="references__article-title">Glucose control and vascular complications in veterans with type 2 diabetes.</span><span class="references__source"><strong>N Engl J Med</strong></span>. <span class="references__year">2009</span>; 360:129–139. doi: 10.1056/NEJMoa0808431<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_22_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=10.1056%2FNEJMoa0808431" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_22_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=19092145" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=360&amp;publication_year=2009&amp;pages=129-139&amp;journal=N+Engl+J+Med&amp;author=W+Duckworth&amp;author=C+Abraira&amp;author=T+Moritz&amp;author=D+Reda&amp;author=N+Emanuele&amp;author=PD+Reaven&amp;author=FJ+Zieve&amp;author=J+Marks&amp;author=SN+Davis&amp;author=R+Hayward&amp;author=SR+Warren&amp;author=S+Goldman&amp;author=M+McCarren&amp;author=ME+Vitek&amp;author=WG+Henderson&amp;author=GD+Huang&amp;title=Glucose+control+and+vascular+complications+in+veterans+with+type+2+diabetes." target="_blank">Google Scholar</a></span></span></li>
<li id="R22" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R22R" class="tab-link-return ref__number"><span class="label">22. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Plutzky J, Bakris G</person-group>. <span class="references__article-title">Sodium/glucose cotransporter 2 inhibitors in patients with diabetes mellitus and chronic kidney disease: turning the page.</span><span class="references__source"><strong>Circulation</strong></span>. <span class="references__year">2018</span>; 137:130–133. doi: 10.1161/CIRCULATIONAHA.117.031422<span class="references__suffix"><a href="https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.117.031422" onclick="newWindow(this.href);return false" target="_blank">Link</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=137&amp;publication_year=2018&amp;pages=130-133&amp;journal=Circulation&amp;author=J+Plutzky&amp;author=G+Bakris&amp;title=Sodium%2Fglucose+cotransporter+2+inhibitors+in+patients+with+diabetes+mellitus+and+chronic+kidney+disease%3A+turning+the+page." target="_blank">Google Scholar</a></span></span></li>
<li id="R23" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R23R" class="tab-link-return ref__number"><span class="label">23. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Hung SC, Kuo KL, Peng CH, Wu CH, Lien YC, Wang YC and Tarng DC</person-group>. <span class="references__article-title">Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease.</span><span class="references__source"><strong>Kidney Int</strong></span>. <span class="references__year">2014</span>; 85:703–709. doi 10.1038/ki.2013.336<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_24_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=10.1038%2Fki.2013.336" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_24_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=24025647" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=85&amp;publication_year=2014&amp;pages=703-709&amp;journal=Kidney+Int&amp;author=SC+Hung&amp;author=KL+Kuo&amp;author=CH+Peng&amp;author=CH+Wu&amp;author=YC+Lien&amp;author=YC+Wang&amp;author=DC+Tarng&amp;title=Volume+overload+correlates+with+cardiovascular+risk+factors+in+patients+with+chronic+kidney+disease." target="_blank">Google Scholar</a></span></span></li>
<li id="R24" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R24R" class="tab-link-return ref__number"><span class="label">24. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Mudaliar S, Alloju S, Henry RR</person-group>. <span class="references__article-title">Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis.</span><span class="references__source"><strong>Diabetes Care</strong></span>. <span class="references__year">2016</span>; 39:1115–1122. doi: 10.2337/dc16-0542<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_25_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=10.2337%2Fdc16-0542" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_25_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=27289124" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=39&amp;publication_year=2016&amp;pages=1115-1122&amp;journal=Diabetes+Care&amp;author=S+Mudaliar&amp;author=S+Alloju&amp;author=RR+Henry&amp;title=Can+a+shift+in+fuel+energetics+explain+the+beneficial+cardiorenal+outcomes+in+the+EMPA-REG+OUTCOME+study%3F+A+unifying+hypothesis." target="_blank">Google Scholar</a></span></span></li>
<li id="R25" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R25R" class="tab-link-return ref__number"><span class="label">25. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Ferrannini E, Mark M and Mayoux E</person-group>. <span class="references__article-title">CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis.</span><span class="references__source"><strong>Diabetes Care</strong></span>. <span class="references__year">2016</span>; 39:1108–1114. doi 10.2337/dc16-0330<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_26_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=10.2337%2Fdc16-0330" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_26_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=27289126" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=39&amp;publication_year=2016&amp;pages=1108-1114&amp;journal=Diabetes+Care&amp;author=E+Ferrannini&amp;author=M+Mark&amp;author=E+Mayoux&amp;title=CV+protection+in+the+EMPA-REG+OUTCOME+trial%3A+a+%E2%80%9Cthrifty+substrate%E2%80%9D+hypothesis." target="_blank">Google Scholar</a></span></span></li>
<li id="R26" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R26R" class="tab-link-return ref__number"><span class="label">26. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Bell RM, Yellon DM</person-group>. <span class="references__article-title">SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection.</span><span class="references__source"><strong>Lancet Diabetes Endocrinol</strong></span>. <span class="references__year">2018</span>; 6:435–437. doi: 10.1016/S2213-8587(17)30314-5<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_27_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=10.1016%2FS2213-8587%2817%2930314-5" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_27_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=29030201" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=6&amp;publication_year=2018&amp;pages=435-437&amp;journal=Lancet+Diabetes+Endocrinol&amp;author=RM+Bell&amp;author=DM+Yellon&amp;title=SGLT2+inhibitors%3A+hypotheses+on+the+mechanism+of+cardiovascular+protection." target="_blank">Google Scholar</a></span></span></li>
<li id="R27" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R27R" class="tab-link-return ref__number"><span class="label">27. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Cherney DZI, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, von Eynatten M, Wanner C</person-group>. <span class="references__article-title">Effects
 of empagliflozin on the urinary albumin-to-creatinine ratio in patients
 with type 2 diabetes and established cardiovascular disease: an 
exploratory analysis from the EMPA-REG OUTCOME randomised, 
placebo-controlled trial.</span><span class="references__source"><strong>Lancet Diabetes Endocrinol</strong></span>. <span class="references__year">2017</span>; 5:610–621. doi: 10.1016/S2213-8587(17)30182-1<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_28_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=10.1016%2FS2213-8587%2817%2930182-1" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_28_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=28666775" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=5&amp;publication_year=2017&amp;pages=610-621&amp;journal=Lancet+Diabetes+Endocrinol&amp;author=DZI+Cherney&amp;author=B+Zinman&amp;author=SE+Inzucchi&amp;author=A+Koitka-Weber&amp;author=M+Mattheus&amp;author=M+von+Eynatten&amp;author=C+Wanner&amp;title=Effects+of+empagliflozin+on+the+urinary+albumin-to-creatinine+ratio+in+patients+with+type+2+diabetes+and+established+cardiovascular+disease%3A+an+exploratory+analysis+from+the+EMPA-REG+OUTCOME+randomised%2C+placebo-controlled+trial." target="_blank">Google Scholar</a></span></span></li>
<li id="R28" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R28R" class="tab-link-return ref__number"><span class="label">28. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Jardine
 MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, 
Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, 
Levin A, Pollock C, Wheeler DC, Xie J, Zhang H, Zinman B, Desai M, 
Perkovic V</person-group>; CREDENCE study investigators. <span class="references__article-title">The
 Canagliflozin and Renal Endpoints in Diabetes with Established 
Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and 
baseline characteristics.</span><span class="references__source"><strong>Am J Nephrol</strong></span>. <span class="references__year">2017</span>; 46:462–472. doi: 10.1159/000484633<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_29_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=10.1159%2F000484633" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_29_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=29253846" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=46&amp;publication_year=2017&amp;pages=462-472&amp;journal=Am+J+Nephrol&amp;author=MJ+Jardine&amp;author=KW+Mahaffey&amp;author=B+Neal&amp;author=R+Agarwal&amp;author=GL+Bakris&amp;author=BM+Brenner&amp;author=S+Bull&amp;author=CP+Cannon&amp;author=DM+Charytan&amp;author=D+de+Zeeuw&amp;author=R+Edwards&amp;author=T+Greene&amp;author=HJL+Heerspink&amp;author=A+Levin&amp;author=C+Pollock&amp;author=DC+Wheeler&amp;author=J+Xie&amp;author=H+Zhang&amp;author=B+Zinman&amp;author=M+Desai&amp;author=V+Perkovic&amp;title=The+Canagliflozin+and+Renal+Endpoints+in+Diabetes+with+Established+Nephropathy+Clinical+Evaluation+%28CREDENCE%29+study+rationale%2C+design%2C+and+baseline+characteristics." target="_blank">Google Scholar</a></span></span></li>
<li id="R29" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R29R" class="tab-link-return ref__number"><span class="label">29. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Pecoits-Filho R, Perkovic V</person-group>. <span class="references__article-title">Are SGLT2 inhibitors ready for prime time for CKD?</span><span class="references__source"><strong>Clin J Am Soc Nephrol</strong></span>. <span class="references__year">2018</span>; 13:318–320. doi: 10.2215/CJN.07680717<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_30_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=10.2215%2FCJN.07680717" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_30_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=28893920" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=13&amp;publication_year=2018&amp;pages=318-320&amp;journal=Clin+J+Am+Soc+Nephrol&amp;author=R+Pecoits-Filho&amp;author=V+Perkovic&amp;title=Are+SGLT2+inhibitors+ready+for+prime+time+for+CKD%3F" target="_blank">Google Scholar</a></span></span></li>
<li id="R30" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R30R" class="tab-link-return ref__number"><span class="label">30. </span></a>Boehringer Ingelheim. <span class="references__article-title">Boehringer
 Ingelheim and Lilly announce an academic collaboration with University 
of Oxford to investigate the effects of empagliflozin in people with 
chronic kidney disease.</span><a class="references__uri" href="https://www.boehringer-ingelheim.com/EMPA-KIDNEY">https://www.boehringer-ingelheim.com/EMPA-KIDNEY</a>. Accessed May 22, 2018.<span class="references__suffix"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;title=Boehringer+Ingelheim+and+Lilly+announce+an+academic+collaboration+with+University+of+Oxford+to+investigate+the+effects+of+empagliflozin+in+people+with+chronic+kidney+disease." target="_blank">Google Scholar</a></span></span></li>
<li id="R31" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R31R" class="tab-link-return ref__number"><span class="label">31. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Tonelli M, Agarwal S, Cass A, Garcia Garcia G, Jha V, Naicker S, Wang H, Yang CW, O’Donoghue D</person-group>. <span class="references__article-title">How to advocate for the inclusion of chronic kidney disease in a national noncommunicable chronic disease program.</span><span class="references__source"><strong>Kidney Int</strong></span>. <span class="references__year">2014</span>; 85:1269–1274. doi 10.1038/ki.2012.488<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_32_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=10.1038%2Fki.2012.488" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_32_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.035901&amp;key=23407433" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=85&amp;publication_year=2014&amp;pages=1269-1274&amp;journal=Kidney+Int&amp;author=M+Tonelli&amp;author=S+Agarwal&amp;author=A+Cass&amp;author=G+Garcia+Garcia&amp;author=V+Jha&amp;author=S+Naicker&amp;author=H+Wang&amp;author=CW+Yang&amp;author=D+O%E2%80%99Donoghue&amp;title=How+to+advocate+for+the+inclusion+of+chronic+kidney+disease+in+a+national+noncommunicable+chronic+disease+program." target="_blank">Google Scholar</a></span></span></li>
<li id="R32" class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R32R" class="tab-link-return ref__number"><span class="label">32. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Schiffrin EL, Lipman ML, Mann JF</person-group>. <span class="references__article-title">Chronic kidney disease: effects on the cardiovascular system.</span><span class="references__source"><strong>Circulation</strong></span>. <span class="references__year">2007</span>; 116:85–97. doi: 10.1161/CIRCULATIONAHA.106.678342<span class="references__suffix"><a href="https://www.ahajournals.org/doi/10.1161/circulationaha.106.678342" onclick="newWindow(this.href);return false" target="_blank">Link</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=116&amp;publication_year=2007&amp;pages=85-97&amp;journal=Circulation&amp;author=EL+Schiffrin&amp;author=ML+Lipman&amp;author=JF+Mann&amp;title=Chronic+kidney+disease%3A+effects+on+the+cardiovascular+system." target="_blank">Google Scholar</a></span></span></li>
</ul>
</div>
</div>
